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SUMMARY 
Mono- or poly-ADP-ribosylation of proteins in cells is mediated in response to 
different stress conditions, such as oxidative stress, DNA damage, or ionizing 
radiation, and is associated with the development of cancer as well as other 
pathological conditions. Biochemically, the ADP-ribose moiety of NAD+ is transferred 
by intracellular diphtheria toxin-like ADP-ribosyltransferases (ARTDs) onto specific 
acceptor amino acids (MARylation) or to already attached ADP-ribose units 
(PARylation). Recently, the combination of selective ADP-ribosylation enrichment 
techniques with mass spectrometric analysis enabled the proteome-wide identification 
of ADP-ribosylated proteins in different cell types exposed to various stress 
conditions. However, an in-depth unbiased identification of all ADP-ribosylated 
proteins (i.e. the ADP-ribosylome) and their qualitative and quantitative changes 
during various stress conditions has been missing. Thus, the aims of the present thesis 
were to elucidate the changes in the cellular ADP-ribosylome under different degrees 
of oxidative stress. 
First, we identified the basal as well as the oxidative stress-induced ADP-
ribosylome in HeLa cells using a newly developed enrichment protocol based on the 
Af1521 macrodomain and subsequent mass spectrometry analysis of modified 
peptides. While the basal ADP-ribosylome mainly contained cytoplasmic proteins, the 
H2O2-induced ADP-ribosylome was mainly characterized by nuclear proteins with 
DNA and RNA binding properties. Second, we improved the mass spectrometric 
analysis by utilizing the unique features of ADP-ribose fragmentation to build an 
ADP-ribosylation specific method based on the combination of HCD and EThcD 
fragmentations. The high-quality spectra obtained with this method allowed us to 
identify a lysine-ADP-ribosylation motif. Third, we developed a targeted proteomics 
method based on parallel reaction monitoring (PRM) to quantify oxidative stress-
induced ADP-ribosylation sites in various cell types. We identified two types of ADP-
ribosylated proteins: stably ADP-ribosylated proteins maintaining a constant 
modification level independent of H2O2 treatment and H2O2-induced ADP-ribosylated 
proteins, which are significantly ADP-ribosylated upon H2O2. Upon treatment with 
low H2O2 concentrations, reduced ADP-ribosylation levels for certain acceptor sites 
were detected. Moreover, the analysis of ovarian cancer cells revealed variable basal 
and oxidative stress-induced ADP-ribosylation levels of defined proteins.  
Together, the developed methods allow to reproducibly identify and assign 
ADP-ribose acceptor sites and to quantify the cellular ADP-ribosylome. The 
application of these mass spectrometry methods will improve understanding the 
function of cellular ADP-ribosylation in different pathological conditions. 
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ZUSAMMENFASSUNG 
Mono- und poly-ADP-Ribosylierungen sind posttranslationale Proteinmodifikationen 
in Säugetierzellen, die während Stressreaktionen katalysiert werden können. Beispiele 
für solche Stressreaktionen sind oxidativer Stress, DNA-schäden, ionisierende 
Bestrahlung und die damit assoziierten pathologischen Veränderungen. Biochemisch 
wird ADP-Ribosylierung durch intrazelluläre Diptheria-Toxin ähnliche ADP-
Ribosyltransferasen (ARTDs) katalysiert. Dabei wird die ADP-Ribose von NAD+ auf 
eine spezifische Aminosäure eines Zielproteins (MARylation) oder ein bereits ADP-
ribosyliertes Protein (PARylation) übertragen. Die selektive Anreicherung von ADP-
ribosylierten Proteinen oder Peptiden in Kombination mit massenspektrometrischen 
Messungen führte kürzlich zur Identifikation von diversen ADP-Ribosylierungsstellen 
im Proteom (ADP-Ribosylom) bei verschiedenen Stressreaktionen in 
unterschiedlichen Zelltypen. Bis her fehlte allerdings die Identifikation von allen 
möglichen ADP-Ribosylierungsstellen sowie deren quantitative Veränderung während 
verschiedenen Stressreaktionen. Das Ziel der vorliegenden Arbeit war es, alle ADP-
ribosylierten Proteine (d.h. das gesamte ADP-Ribosylom) während verschiedenen 
oxidativen Stressstärken zu identifizieren und zu quantifizieren.  
In einem ersten Schritt wurde durch die Etablierung eines AF1521-basierten 
Anreicherungsprotokolls das basale sowie das H2O2-induzierte ADP-Ribosylom in 
HeLa Zellen bestimmt. Im Gegensatz zum basalen ADP-Ribosylom, welches 
hauptsächlich zytoplasmatische Proteine enthielt, setzte sich das H2O2-induzierte 
ADP-Ribosylom aus Kernproteinen zusammen, die DNA und RNA-
Bindungseigenschaften besitzen. Zweitens wurde die massenspektrometrische 
Methode weiter optimiert. Hierzu wurden die Eigenschaften der ADP-Ribose-
Fragmentierung genutzt und eine kombinierte HCD EThcD Fragmentierungsmethode 
etabliert. Es wurden hochqualitative Spektren aufgenommen, welche die 
Identifizierung eines Lysin-ADP-ribosylierungsmotivs ermöglichten. Drittens haben 
wir eine quantitative proteomweite Methode basierend auf dem Parallel Reaction 
Monitoring (PRM) entwickelt, um das H2O2-induzierte ADP-Ribosylom in 
verschieden Zelllinien zu untersuchen. Mit dieser Methode war es möglich, zwei 
Gruppen von ADP-ribosylierten Proteinen zu identifizieren: ADP-ribosylierte 
Proteine, die unabhängig von der H2O2-Behandlung konstant modifiziert waren und 
Proteine, bei denen ADP-Ribosylierung signifikant durch H2O2 induziert wurden. Bei 
sehr geringem oxidativen Stress wurde eine reduzierte ADP-Ribosylierung für gewisse 
untersuchte Modifikationsstellen beobachtet. Darüber hinaus konnten wir in 
verschiedenen Krebszelllinien variable basale und oxidativer Stress induzierte ADP-
Ribosylierung bestätigen.  
Zusammenfassend erlaubt uns die neu entwickelte Methode ADP-Ribose 
Akzeptorstellen zu identifizierung und zelluläre ADP-Ribosylierung reproduzierbar zu 
quantifizieren. Anhand dieser massenspektrometrischen Anwendung wird es zukünftig 
möglich sein, die Funktion von zellulärer ADP-Ribosylierung unter unterschiedlichen 
pathologischen Bedingungen zu untersuchen.  
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PAR    poly-ADP-ribose 
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PBD    PAR binding domain 
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Q    quadrupole  
ROS    reactive oxygen species 
SILAC    stable isotope labeling by amino acids in cell culture 
SRM    single reaction monitoring  
SSB    single strand break 
SVP    snake venom phosphodiesterase  
WT    wildtype 
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1. INTRODUCTION 
1.1. Protein posttranslational modifications - increasing protein complexity  
Genome sequencing has identified 20’000-25’000 coding genes in the human genome 
[5]. Following the classical molecular biology paradigm, “one gene – one protein”, the 
number of different proteins in the cells equals the number of genes. However, the 
recent advantages in decoding and annotating the total protein content of human cells 
(i.e. the human proteome) [6, 7] revealed an overall higher complexity of the proteome 
compared to the genome. The term proteoform was, therefore, introduced to describe 
various protein forms of one gene [8]. This increased complexity of the proteome 
stems from two sources. First source is genome variability and RNA metabolism (e.g. 
alternative splicing, RNA editing, single-nucleotide polymorphisms) [9]. Second 
source is alterations in the protein structure coming either from proteolytic cleavage or 
chemical modification of the amino acid side chains termed protein posttranslational 
modification (PTM). Among the well-studied examples of PTMs are phosphorylation, 
acetylation, methylation, and ubiquitination.  
Cells utilize PTMs, which dynamically regulate protein activity, localization, 
and interactions, to quickly respond to changing environmental conditions. The 
majority of PTMs function in modification cycles, involving sets of enzymes, which 
write, read and erase the modification. With over 300 different PTMs known, it may 
not be surprising that 5% of the human genome encodes proteins responsible for 
catalyzing the metabolism of PTMs [10]. The transient nature of PTMs enables them 
to act as a regulatory switch, activating or inactivating enzymes. The best-known 
example is phosphorylation, which regulates kinase activity in many signaling 
cascades. Around 30% of the proteome is expected to be phosphorylated at any given 
time point [11]. Together, these events can potentially generate about 50-60 
proteoforms. Thus, the human proteome is estimated to consist of up to 1.5 million 
proteoforms [12], although the exact number remains elusive. 
Understanding the PTMs cellular function and dynamics is an important task of 
molecular biology. However, the tools to study PTMs are limited and many PTMs 
were discovered using basic biochemical approaches applied to single isolated proteins 
[13]. The development of mass spectrometry-based proteomics boosted the analysis of 
PTMs [12].  
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1.2. ADP-ribosylation is a highly dynamic protein posttranslational 
modification 
ADP-ribosylation is a highly dynamic, ancient, reversible PTM (Figure 1). Originally 
studied in bacteria as a mechanism of toxin action [14], ADP-ribosylation is also 
present in archaebacteria and eukaryotic cells. The reaction of ADP-ribosylation starts 
with the transfer of an ADP-ribose moiety from NAD+ onto the target protein by 
specific enzymes (Figure 1, discussed in 2.3). This initiation reaction generates mono-
ADP-ribosylation (MARylation). Several enzymes can then extend MARylation and 
attach additional ADP-ribose units producing poly-ADP-ribosylation (PARylation). 
Whereas MARylation is widely observed within the entire taxon, PARylation is 
limited mainly to multicellular eukaryotes [15]. Moreover, the half-life of PAR is short 
compared to the relatively stable MAR [16].  
The changes that PARylation triggers in modified proteins and cellular 
environment explain the transient nature of the modification. PAR is a large 
modification, sometimes exceeding the size of the modified protein. Carrying two 
negative charges per ADP-ribose unit, it can vastly change the physical properties of 
the modified proteins. Moreover, synthesis of PAR consumes NAD+ molecules, an 
essential cofactor in energy metabolism. The NAD+ pool can be almost completely 
Figure 1. ADP-ribosylation cycle. 1. Initiation step – MARylation reaction 2. Elongation step – 
PARylation reaction. n is a number of ADP-ribose units attached to the MARylated protein and the 
number of consumed NAD+ molecules. 3a. Degradation of PAR chains. 3b. Modification reaction - 
hydrolysis of pyrophosphate bond. Phosphoribose residue stays on the proteins.  4. Complete reversion 
of MARylation. The enzymes reversing the ADP-ribosylation and their specifically is indicated. 5. An 
unknown step of phosphoribose cleavage from modified proteins.  
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depleted at severe genotoxic stress [17]. In these cases, following ATP depletion leads 
to cell death [16].  
Two types of chemical linkages between ADP-ribose and an acceptor site exist. 
An ester linkage connects the modification to acidic amino acids (aspartic and 
glutamic acids), whereas a ketamine bond is formed at lysines and arginines (Figure 2) 
[4]. Additionally, cysteine, diphthamide, phosphoserine, and asparagine serve as  
possible acceptor sites of ADP-ribosylation [18]. Interestingly, non-enzymatic 
conjugation of ADP-ribose to lysine formed via Amadori rearrangement, called 
glycation, exists, occurring at high pH values and high concentrations of free ADP-
ribose [19]. The non-physiological conditions of the reaction make it arguable whether 
it occurs in cells.  
1.3. ARTDs – intracellular writers of ADP-ribosylation 
Several groups of enzymes catalyze ADP-ribosylation: ADP-ribosyltransferases 
(ARTs) and sirtuins 1 and 3. The ARTs family is subdivided into ARTDs (diphtheria 
toxin-like ARTs) and ARTCs (the structurally distinct cholera toxin-like ARTs) based 
on their structural similarity to bacterial toxins. ARTCs are located at the cellular 
membrane and mainly modify extracellular proteins [20], whereas ARTDs are located 
in different cellular compartments and responsible for the modification of intracellular 
proteins (Table 1) [15]. 
There are 17 members of ARTDs (also known as PARPs) in humans.  The enzymes 
are grouped together based on their structural features [15]. Despite their similarity, 
ARTDs show various enzymatic activities. The majority of ARTDs only catalyze 
MARylation [21]. ARTD1 is the first studied enzyme with PARylation activity. The 
ability to produce PAR chains is associated with the characteristic H-Y-E motif within 
the catalytic domain [22]. Indeed, four enzymes with this motif perform PARylation: 
ARTD1, ARTD2, ARTD5 and 6.  
Figure 2. Chemical linkages between ADP-ribose and four best-studied acceptor sites. The 
numbers on the ribose ring indicate the stereo-specificity of a specific linkage. Adapted from [4]. 
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Table 1. Summary of ARTD family member’s reported enzymatic activity, catalytic 
motif, and cellular localization. Modified from [21], [4]. 
 
ARTD1 is a 114 kDa nuclear protein consisting of a catalytic domain, a DNA 
binding domain (two Zn-finger motifs and one Zn finger domain), a nuclear 
localization signal, an automodification domain (including a BRCA1 C-terminal 
motif), and a WGR motif [23, 24]. PAR chains produced by ARTD1 can reach a total 
length of up to 200 units in vitro [25]. The elongation reaction is dependent on E988 in 
the catalytic domain of ARTD1. Mutation of E988, however, does not inactivate 
ARTD1 but limits its activity to MARylation [26]. This fact indicates an 
enzymatically different mechanism of the elongation reaction in comparison to the 
initiation reaction. Moreover, ARTD1 also branches the polymers every 20-40 ADP-
ribose units [27, 28]. A 2”-1” O-glycosidic ribose bond connects ADP-ribose units in 
Enzyme Motif Activity Localization 
ARTD1 (PARP1) H-Y-E PAR nucleus 
ARTD2 (PARP2) H-Y-E PAR nucleus 
ARTD3 (PARP3) H-Y-E MAR nucleus, cytoplasm 
ARTD4 (vPARP, PARP4) H-Y-E MAR 
nucleus, exosome, cell 
membrane 
ARTD5 (PARP5a, TNKS1) H-Y-E PAR nucleus, Golgi, cytoplasm 
ARTD6 (PARP5b, TNKS2) H-Y-E PAR nucleus, Golgi, cytoplasm 
ARTD7 (PARP15, BAL3) H-Y-I MAR cytoplasm 
ARTD8 (PARP14, BAL2) H-Y-I MAR nucleus, cell membrane 
ARTD9 (PARP9, BAL1) Q-Y-T inactive 
nucleus, cytoplasm, cell 
membrane 
ARTD10 (PARP10) H-Y-I MAR nucleus, cytoplasm 
ARTD11 (PARP11) H-Y-I MAR nucleus, cytoplasm 
ARTD12 (PARP12) H-Y-I MAR cytoplasm 
ARTD13 (PARP13, ZC3HAV1) Y-Y-V inactive cytoplasm 
ARTD14 (PARP7, tiPARP) H-Y-I MAR nucleus, cytoplasm 
ARTD15 (PARP16) H-Y-I MAR 
cell membrane, 
endoplasmic reticulum 
ARTD16 (PARP8) H-Y-I MAR cytoplasm 
ARTD17 (PARP6) H-Y-I MAR cytoplasm 
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an elongation reaction, whereas a 2”-1” glycosidic bond is formed upon branching. 
Indeed, the ARTD1 catalytic pocket can fit ADP-ribose in both orientations (rotation 
of 180o) for elongation and branching [29]. However, the physiological function of 
branched polymers is still unclear. 
ARTD5 and 6 (also known as tankyrases (TNKS) are the last ARTD enzymes 
with proven PARylation activity. However, they lack branching activity and produce 
only short linear PAR up to 20 units long [30]. They share a highly conserved 
structure, which is different from other ARTD members [31]. Although initially 
localized to the nucleus, ARTD5 and 6 are present in the cytoplasm, Golgi complex 
and transport vesicles [21, 32]. The activity of ARTD5 and 6 is linked to the 
regulation of protein turnover by ubiquitination [33]. 
The remaining ARTD family members catalyze MARylation (except ARTD9 
and ARTD13, which are postulated to be inactive). Despite the fact that ARTD3 has 
the characteristic H-Y-E motif, it performs MARylation only [34]. The presence of R 
instead of M890 in the ARTD3 catalytic pocket partially explains the difference in the 
enzymatic activity of ARTD1 and ARTD3 [31]. Together with ARTD1 and ARTD2, 
ARTD3 is commonly referred to as a DNA-dependent ARTD. ARTD1 recognizes 
DNA via zinc-finger domains, whereas ARTD3 and ARTD2 have WGR domains 
allowing them to bind DNA and/or RNA [35]. Interestingly, the type of DNA template 
and specific DNA breaks define the activity of the enzymes [36]. The activation upon 
binding to DNA breaks defines their key function in DNA repair (discussed in more 
detail in 1.6.1).   
Other ARTDs localize to various cellular compartments and have diverse 
domain organizations. ARTD4 is another enzyme with an H-Y-E motif and only 
MARylation activity. The inability of ARTD3 and ARTD4 to produce PAR indicates 
that additional structural differences discriminate between PARylation and 
MARylation activity. Interestingly, three enzymes, i.e. ARTD7, ARTD8 and ARTD9 
possess macrodomains (described below) which enable them to bind ADP-ribosylated 
proteins [29]. However, due to the limited tools to study MARylation, the structure, 
activity, and function of these enzymes stay poorly understood.  
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1.4. ADP-ribose binding domains 
In various cellular signaling events, PAR and MAR are recognized by different protein 
domains, so-called readers. Depending on the binding affinity, the readers are either 
specific for PAR or able to bind both PAR and MAR (Figure 3). The PAR binding 
domain, the PAR binding zinc finger (PBZ), and the WWE domain are specific PAR 
binders. The macrodomain is an example of a protein fold with both PAR and MAR 
binding affinity. The first discovered PAR-binding motif was the PAR binding 
domain. It is mainly present in proteins involved in DNA repair and chromatin 
remodeling [37]. The PAR binding zinc finger is another example of a domain which 
specifically binds PAR [38]. However, only two proteins involved in the DNA damage 
response i.e. APFL and CHFR, possess a PBZ domain [39].  
The WWE domain functionally links ADP-ribosylation and ubiquitination since 
it is mainly found in ubiquitin ligases and several ARTD family members [40]. The 
domain received its name by the presence of three characteristic amino acids (W – 
tryptophan, E – glutamate). The domain functions through the recognition of an iso-
ADP-ribose moiety, surrounding the α(1→2) O-glycosidic bonds [41] and can, thus, 
specifically interact with PAR but not MAR. 
Figure 3. ADP-ribose binding domains. The colored areas on the ADP-ribose structure indicate the 
known affinity of the domains. Modified from [2]. 
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The macrodomain fold is a conserved domain of 130–190 amino acids [42, 43], 
which binds to various forms of ADP-ribose including free ADP-ribose [44]. This 
affinity toward different versions of ADP-ribose allows macrodomains to bind both 
PARylated and MARylated proteins. Ten macrodomains, e.g. histone variant 
macroH2A and O-acetyl-ADP-ribose deacetylase (MacroD1), are present in human 
cells. Interestingly, macrodomains were also identified in archaebacteria [45]. 
Moreover, archaebacterial protein Af1521 from Archaeoglobus fulgidus has one of the 
highest identified affinities to ADP-ribose (Kd of 130 nM) [44]. Based on this high 
affinity, Af1521 was successfully tested in pull-downs of ADP-ribosylated proteins 
from complex cellular mixes [46]. In addition to their PAR binding activity, some 
macrodomain-containing proteins including Af1521 hydrolyze and release ADP-
ribose from MARylated proteins modified on glutamic and aspartic acids [47, 48]. 
Additional ADP-ribose binding domains, e.g. the OB-fold or the BRCT domain, have 
been discovered recently. However, for many of them, the binding affinity has not 
been extensively studied yet [2].  
1.5. Erasers/Modifiers: reversing the modification  
Degradation of PAR chains and removal of MAR from proteins complete the cycle of 
ADP-ribosylation. Depending on their activity, ADP-ribosylation catabolizing 
enzymes are grouped into three categories. The first group is active against PAR 
chains; the second group catabolizes MARylation: the last is modifying ADP-
ribosylation (Table 2).  
Two enzymes can hydrolyze PAR chains: PAR glycohydrolase (PARG, [49]) 
and PAR hydrolase (ARH3, [50]). PARG has five isoforms, produced from one gene 
by alternative splicing and localized to different cellular compartments [51]. The most 
abundant 110 kDa isoform of PARG is a nuclear enzyme responsible for the fast 
turnover of PAR upon DNA damage. Despite the relatively low abundance, PARG 
degrades PAR chains within minutes after a certain DNA damage stimulus [52]. 
PARG KO mice die during embryonic development, and even downregulation of 
PARG activity sensitizes cells to DNA damaging agents. These observations indicate 
an important function of PARG in stress responses and DNA repair [53]. PARG, as 
well as ARH3, possess endo- and exoglycosidase activity, however, are unable to 
cleave  MAR  from  proteins  (Figure 1).  ARH1  was  the  first  identified  enzyme  to 
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Table 2. Summary of ADP-ribosylation hydrolases indicating their enzymatic activity 
and cellular localization. Modified from [16]. 
 
completely reverse the modification specifically from arginines [54]. As mentioned  
before, some of the macrodomains have the ability to cleave ADP-ribose from aspartic 
and glutamic acids. The enzyme responsible for removing MARylation from lysines is 
yet to be discovered.  
Enzymes with phosphatase activity have the ability to modify ADP-ribosylation. 
Among the known examples are snake venom phosphodiesterase (SVP) and the 
NUDIX family. SVP is a phosphatase which cleaves the pyrophosphate bond between 
adenosine monophosphate and phosphoribose, leaving the latter attached to the protein 
[54]. The NUDIX family of pyrophosphatases consists of 24 genes in humans. 
NUDIX family analogs are found in E. coli, yeast, and archaebacteria. NUDT9 and 
NUDT14 have experimentally proven hydrolase activity against ADP-ribose, and 
NUDT6 has a similar predicted activity [55]. Recently, the E. coli enzyme EcRppH 
and human NUDT16 were shown to reverse ADP-ribosylation of proteins in vitro 
[56]. These enzymes may play a major role in the elimination of free ADP-ribose after 
oxidative stress and PAR degradation by PARG.  
1.6. Function of ARTD1-mediated PARylation  
The diversity of ARTD enzymes and their localization indicate the involvement of 
ADP-ribosylation in various cellular events. Little is still known about the function 
and regulation of MARylation. The few examples of studied MARylation signaling 
Enzyme Isoforms/Proteins Activity Localization 
PARG 
111 kDa 
Endo- and exoglycosidase, 
to PAR 
nucleus 
102, 99, 60 kDa cytoplasm 
55 kDa mitochondria 
ARH1 39 kDa 
Glycosidase (specific to R), 
to MAR 
cytoplasm 
ARH3 39 kDa 
Endo- and exoglycosidase, 
to PAR 
nucleus, 
cytoplasm, 
mitochondria 
Macrodomains 
MacroD1/MDO1 
35 kDa 
Glycosidase (specific to D 
and E), to MAR 
nucleus, 
cytoplasm 
MacroD2/MDO2 
50 kDa 
C6orf130/TARG 
17 kDa 
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include transcriptional regulation of STAT6 signaling (ARTD8 activity) [57] and 
regulation of inflammation via NF-κB Signaling (ARTD10 activity) [58]. The main 
obstacles in MARylation research are the limited number of available methods and 
poor understanding of ARTD activity, specifically stimuli, which trigger a response. 
On the other hand, stimuli inducing PAR are well known and include genotoxic and 
oxidative stress.  
1.6.1. Role of ARTD1 in genome stability 
ADP-ribosylation has a key function in DNA strand break repair, a fundamental 
cellular pathway ensuring genome stability. The type of generated DNA break defines 
a specific repair pathway. Single-strand break (SSB) repair is executed via base 
excision adducts. Double-strand breaks (DSB) are repaired via non-homologous end 
joining (NHEJ) or homologous recombination (HR) [59]. The HR pathway is error-
free and preferred in cells, however, can be executed only during late S- and G2-
phases, where sister chromatids are available as templates [60]. Accumulation of PAR 
was observed in response to various genotoxic agents (e.g. ionizing radiation, 
alkylating agents). Thus, ADP-ribosylation plays a role in all four repair pathways. 
ARTD1, ARTD2, and ARTD3 are the nuclear enzymes associated with DNA repair. 
ARTD1, however, is responsible for up to 90% of occurring PARylation [61]. ARTD1 
recognizes and binds both SSB and DSB with its DNA binding (DB) domain [62]. 
Binding to DNA activates ARTD1 in vitro by inducing conformational rearrangements 
within the WGR domain [63] and, therefore, increasing its activity up to 500 fold. 
ARTD1 activation leads to the fast accumulation of PAR chains in the nucleus. 
Among the targets of ARTD1 are ARTD1 itself (auto-modification), histones, and 
topoisomerase I [17, 64]. Modification of histones leads to the accumulation of 
negative charges and the relaxation of the chromatin structure. This enables easy 
access of DNA repair proteins to the DNA breaks [65]. Another function of PAR in 
DNA repair is the recruitment of key DNA repair proteins to the site of the damage. 
E.g., recruitment of XRCC1 (in SSB repair) and ATM, Mre11, and Nbs1 (in HR) is 
dependent on PAR formation and ARTD1 activity [64, 66]. An XRCC1 PAR-binding 
domain was identified recently [67] and the presence of PAR binding protein 
sequences was hypothesized for ATM and Mre11 [64, 68]. Nevertheless, the exact 
mechanism of recruitment for other proteins has not been extensively studied.  
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Despite the major role of ARTD1 in genome stability, ARTD1 KO mice are 
viable and fertile, and show residual PAR formation upon genotoxic treatment [69], 
which can be explained by functional redundancy within the ARTD family. Moreover, 
the ARTD1 and ARTD2 double KO mice are not viable and die at the gastrulation 
stage [70]. Interestingly, HR still functions in an ARTD1-/- background. ARTD1-/- 
mice are not predisposed to tumor formation [71], and Rad51 foci are still formed in 
response to hydroxyurea in ARTD1-/- cells [72]. Nevertheless, inhibition of ARTD1 
leads to an increase in HR [72] and micronuclei formation [73], confirming an 
important role of ARTD1 in genome stability. Interestingly, the double knockout of 
ARTD1 together with other DNA repair proteins (e.g. XRCC5 [74] or ATM [75]) is 
embryonically lethal, whereas single KO mouse models of these proteins are viable, 
indicating their synergistic key function in DNA repair.  
1.6.2. Role of ARTD1 in oxidative stress 
A well-known trigger of genomic instability is oxidative stress. Induction of PAR in 
the nucleus upon H2O2 treatment was detected long ago. However, the precise 
mechanism on how PARylation contributes to the oxidative stress response is still 
unclear. Oxidative stress is a cellular condition caused by a misbalance of reactive 
oxygen species (ROS) accumulation and their neutralization. Cellular ROS i.e. 
superoxide radicals (O2
-), hydrogen peroxide (H2O2) and hydroxyl radicals (·OH) 
come from endogenous and exogenous sources [76]. Exogenous sources include UV 
light, smoke, and ionizing radiation. Endogenous ROS are produced in mitochondria 
and peroxisomes. Since production of ROS is an unavoidable product of cellular 
metabolism, cells are equipped with an antioxidant defense system. The antioxidant 
defense includes superoxide dismutase, catalase, and glutathione peroxidase, which 
neutralize O2·
-,  and  H2O2, respectively [77]. Pathological conditions like chronic 
inflammation and hypoxia induce the accumulation of ROS, which cannot be 
effectively inactivated via the antioxidant defense. ROS cause macromolecule 
oxidation, thereby damaging lipids, proteins and nucleic acids, i.e. DNA. ROS-
induced DNA damage is mainly repaired via the BER pathway, whose execution 
depends on ARTD1 and PARylation. For a long time, oxidative stress-induced 
PARylation was thought to be associated with binding and activation of ARTD1 to 
sites of DNA damage. Recent studies, however, suggest new functions of ARTD1. 
Oxidative stress-induced DNA damage alone is not sufficient to induce PAR 
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formation. Moreover, activation of ARTD1 is dependent on the balance of PKCα 
dependent eviction of HMGB1 from the nucleus [78]. Euchromatic regions are 
believed to be highly sensitive to genotoxic stress and thus should have a high level of 
PARylation. However, stress-induced PARylation is present on heterochromatic 
regions [79]. PAR accumulation at heterochromatic regions potentially protects 
histone marks and induces chromatin relaxation, pointing at an epigenetic function of 
ARTD1 and PARylation in genotoxic stress [79]. These recent observations indicate 
the broad function of ARTD1 and PARylation in oxidative stress and further studies 
should be performed to fully understand it.  
1.6.3. ARTD1-mediated PARylation functions beyond stress signaling 
Besides its function in genotoxic stress signaling and oxidative stress, ARTD1 
regulates transcription and cell differentiation. ARTD1 is enriched at the promoters of 
active genes and enhancers, indicating its function in regulation of gene expression 
[80]. PAR chains promote recruitment of several chromatin modifier proteins: 
members of the polycomb group, transcriptional repressor proteins, and deacetylase 
complexes [81]. Moreover, ARTD1 was also shown to bind nucleosomes with intact 
DNA [82]. Physiologically occurring DNA breaks can activate ARTD1, e.g. DNA 
breaks induced by topoisomerase II β [83]. Interestingly, similar functions were 
reported for other DNA-binding ARTDs. ARTD2 negatively regulates SIRT1 [84] and 
ARTD3 is enriched on developmental genes [85]. These observations point to a 
function of PARylation in transcriptional regulation. PARylation mediated by ARTD1 
also regulates cell differentiation. E.g, maturation of adipocytes is dependent on 
ARTD1 binding to PPARγ2 [86]. Similarly, ARTD1 regulates differentiation of 
astrocytes, osteoclasts, and myocytes as well as immune cells [16].   
1.7. ADP-ribosylation inhibitors as therapeutic agents  
Due to the critical role of ADP-ribosylation in genomic stability, ARTDs activity is 
considered as a valuable target for therapeutic intervention. The first inhibitor 
targeting ARTDs (generally named as PARP inhibitors (PARPi)) was 3-
aminobenzamide (3-AB) developed over 30 years ago by Purnell and colleagues [87]. 
Many developed PARPi have structural similarity to nicotinamide (NAM) (e.g. 3-AB 
or olaparib) and act via blocking the NAM binding pocket within the active site of 
ARTDs. Since ARTD family members are structurally very similar, these PARPi are 
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not specific. Indeed, the screening of a chemical library consisting of 185 compounds 
showed that 56% of tested PARPi also block ARTD2 and 3, and 36% ARTD4 [88]. 
The broad inhibition spectrum of these PARPi leads to problems with understanding 
their mechanism of action. Recently, new chemical structures have been developed, 
i.e. substances targeting the DBD of ARTD1, which potentially can increase the 
specificity of the drugs [89]. 
1.7.1. Mechanism of action of PARP inhibitors 
The exact mechanism on how PARPi kill cancer cells is still debatable. Three theories 
were proposed. “Synthetic lethality” underlies the role of ARTD1 in DNA repair; the 
second theory postulates the trapping of inactivated ARTD1 on chromatin, and the last 
theory explains the mechanism by disturbances in NAD+ metabolism.  
The widely accepted PARPi action mechanism is the “synthetic lethality” 
theory. According to this theory, inactivation of two key genes in one specific pathway 
leads to cell death. However, inactivation of either gene alone is not lethal [90]. In 
cancer, HR is commonly inactivated. Upon ARTD1 inhibition, HR-deficient cancer 
cells accumulate DNA breaks that are either not repaired or inefficiently repaired in an 
error-prone way. Accumulation of unrepaired DNA breaks leads to genomic instability 
and subsequently to cell death [91].  
In recent years, an alternative mechanism of PARPi action was suggested. Based 
on this alternative theory, PARPi trap ARTD1 at sites of DNA damage, and thus 
obstruct DNA repair and transcription [92]. Interestingly, the property of PARPi to 
trap ARTD1 does not correlate with their enzymatic inhibitory property [93]. 
Understanding of this mechanism can potentially help to identify new cancer types 
that are sensitive to PARPi.  
Based on the last theory, the activity of ARTD1 regulates NAD+ concentration 
in the nucleus. SIRT1, another NAD+ consuming enzyme, is activated by increased 
levels of NAD+ in ARTD1-/- cells [94]. This activation leads to the induction of 
transcription factors regulating mitochondrial biogenesis. Cancer cells shift their 
energy metabolism to glycolysis (known as the “Warburg effect”), bypassing slow 
oxidative phosphorylation pathway. Glycolysis provides a fast energy source for 
cancer cells, allowing their accelerated growth rate [95]. Indeed, the activation of 
mitochondria upon PARPi administration potentially restores their involvement in 
energy metabolism and thus kills energy-demanding cancer cells [96].  
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1.7.2. Cancer treatment options with PARP inhibitors 
The attention to PARPi increased when two studies reported sensitivity of BRCA-
deficient cancer cells to PARPi [97, 98]. Plenty of PARPi underwent clinical studies 
for cancer treatment. Recently, the third generation of PARPi was approved for 
monotherapeutic treatment of BRCA negative ovarian cancers and BRCA1/2 or ATM 
negative metastatic castration-resistant prostate cancers [99].  
Due to the key function of BRCA1 and 2 in HR, mutations in BRCA1 and 
BRCA2 are associated with the development of various cancer types. E.g., women 
who carry BRCA1 or BRCA2 gene deletions have a 40% and 20% lifetime risk to 
develop ovarian cancer and breast cancer, respectively [100]. The prevalence of these 
mutations in ovarian cancer is around 10-15% [101], with certain types reaching up to 
44% of diagnosed cases [102]. The cancer phenotype similar to BRCA1 or 2 deletions 
was termed “BRCAness”. The BRCAness phenotype is associated with HR deficiency 
that can be caused by inactivation of the BRCA gene or with a loss-of-function 
mutation in other HR genes [103]. Based on the synthetic lethality theory, BRCAness 
cells should be sensitive to PARPi. However, due to various types of BRCA 
mutations, genomic instability of cancer cells, and complex regulation of cancer cells 
in general, the response to PARPi is hard to predict [103]. Thus, various screening 
methods (BRCA mutations screen, mutation signatures of HR-deficient cells) are used 
to screen and predict a patient’s response to PARPi.  
PARPi can also be administrated in a combination therapy together with other 
cancer therapeutic agents. For many combinations and in various cancer types, the 
severe side effects such as eutropenia, thrombocytopenia, and myelosuppression were 
observed [104, 105]. Nevertheless, some combinatorial therapies showed acceptable 
toxicity, e.g. a combination of olaparib with the microtubular toxin paclitaxel for the 
treatment of breast, non-small cell lung, and ovarian cancer [106]. An aggressive 
triple-negative breast cancer showed a response to PARPi administrated together with 
nicotinamide phosphoribosyltransferase inhibitors [107]. Despite the fact that triple 
negative cancers have a BRCAness phenotype, sensitivity to PARPi is dependent on 
the NAD+ metabolism of these cells. At the moment, 52 clinical studies are evaluating 
the efficiency of PARPi in combination with conventional treatments [108]. Thus, 
further studies should elucidate the PARPi mechanism of action in cancer cells to 
identify sensitive cancer types and to better predict the outcome of a certain treatment. 
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1.8. Shotgun approach to study protein posttranslational modifications  
The application of mass spectrometry to study the cellular proteome started in the 
early 1990s [109]. The “classical” approach to unravel the proteome is the shotgun 
method (also named bottom-up approach) [110]. In this approach, cellular proteins are 
first digested with trypsin or other proteases. The resulting peptide mix is further 
analyzed using liquid chromatography connected to a tandem mass spectrometer (LC-
MS/MS). Subsequent bioinformatics analysis aims to correspond the acquired spectra 
with the theoretical fragmentation of peptides obtained from a protein database. For 
this complex analysis, several algorithms were developed, e.g. Mascot [111] and 
Andromeda [112]. The development of mass spectrometry-based proteomics allows 
the identification of several thousand proteins in one short MS/MS measurement [113, 
114].  
Analysis of PTMs brings an additional level of complexity to proteomic studies. 
The attachment of a chemical group shifts the molecular weight of the peptide, making 
it difficult to assign the correct sequence. The fact that PTMs are only present on a 
small number of peptides in the complex sample increases the complexity of the 
downstream bioinformatics analysis. PTMs change the physical and chemical 
characteristics of modified peptides, which can lead to a lower detection efficiency 
[12]. Depending on the size and localization of a modification, the protease digestion 
can be limited and incomplete, leading to miscleavages. Additionally, the abundance 
of PTMs in the cellular proteome is low, making it challenging to detect them in 
complex mixtures such as cell lysates. More abundant, non-modified peptides cover 
the lower signals of a modified peptides. To increase the identification level of PTMs, 
enrichment steps developed specifically for certain PTMs are necessary. 
1.9. Enrichment strategies for ADP-ribosylation  
In general, enrichment strategies developed for ADP-ribosylation can be divided into 
three categories: chemical enrichments (e.g boronic beads enrichment and 
phosphoenrichment methods), affinity-based enrichments (e.g. using protein-binding 
domains or antibodies), and click-chemistry methods in combination with special 
ADP-ribose labeling approaches.  
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1.9.1. Chemical enrichments 
Okayama et al. first applied boronate beads for purification of ADP-ribosylated 
proteins from rat liver in 1978. In the study, H1 and H2B were identified as acceptors 
of ADP-ribosylation [115]. The mechanism of the enrichment is based on the 
formation of an ester linkage between the boronate group and the 1,2-cis-diol moiety 
of ADP-ribose under alkaline conditions (pH > 8). The release of the bond occurs at 
low pH values (pH < 6). However, such pH changes are not optimal due to the 
chemical sensitivity of the ADP-ribose linkage. Depending on the ADP-ribosylation 
linkage type, ADP-ribose can be lost from the protein during this enrichment 
procedure [116]. Recently, Zhang et al. suggested hydroxylamine (HA) elution as an 
alternative to pH change [117]. During the elution, HA attacks the ester bond formed 
between an aspartic or glutamic acid and ADP-ribose. As a result, released peptides 
gain a characteristic mass shift of +15.01 Da, which is detected by MS/MS (Figure 
4A). Using this approach, Zhang et al. were able to identify 340 ADP-ribosylated 
proteins in HCT116 cells upon exposure to 1 mM H2O2. However, the study was 
performed in a PARG-/- background. The use of wildtype cells with this method 
significantly decreases the identification level of enriched peptides [117]. Moreover, 
the boronate beads also enrich glycoproteins due to the presence of ribose rings in 
their structure.  
Due to the presence of phosphate groups in the ADP-ribose structure, PAR and 
MAR proteins can be enriched with phosphoenrichment techniques. Enrichments with 
TiO2 or IMAC are well developed and standardized methods in phosphoproteomics 
Figure 4. Enrichment of ADR-ribosylated proteins with chemical enrichment methods. A) Boronic 
beads enrichment with HA elution. The arrow points at the bond attacked by HA. B) 
Phosphoenrichment methods for the pull-down of ADP-ribosylation. In this example, TiO2 binding is 
used for phosphoenrichment. The arrow indicates the bond cleaved by SVP. 
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[118]. Indeed, ADP-ribosylated proteins have been identified in phosphoproteomics 
datasets [119]. Daniels et al. have further optimized phosphoenrichment methods for 
in vitro and in vivo ADP-ribosylated samples [120]. An SVP digest of peptides 
introduced before the enrichment aims at increasing the binding as well as decreasing 
the complexity of the modification (Figure 4B). However, in cellular samples, the use 
of this enrichment is limited due to the competition with the more highly abundant 
phosphopeptides.   
1.9.2. Affinity purification with ADP-ribose binding domains 
The first domain used for the enrichment of ADP-ribosylated proteins was the 
macrodomain Af1521 [46]. The combination of Af1521 enrichment with LC-MS/MS 
led to the identification of 235 ADP-ribosylation associated proteins in HeLa cells 
exposed to various stress conditions [121]. However, since the study has not assigned 
the ADP-ribosylated acceptor sites, it is not clear whether all identified proteins were 
ADP-ribosylated or only interacted with PAR, MAR or modified proteins.  
1.9.3. Specific ADP-ribose labeling approaches 
Various labeling methods were developed for several PTMs, allowing a specific 
enrichment via an introduced tag. To label ADP-ribosylation, various analogues of 
NAD+ have been developed.  It is hard to perform in vivo labeling of ADP-
ribosylation, because NAD+ analogues synthesized so far cannot penetrate cells due to 
their size. Thus, using NAD+ analogues lacks the biologically relevant context, as the 
linkage to proteins is performed after disruption of the cellular compartments. All 
published methods so far are performed in vitro or using cellular lysates. 
Endogenously present ARTDs can catalyze the labeling with biotinylated NAD+ [122], 
or 1,-N6-alkyne-NAD [123]. Another NAD+ analogue, 8-Bu(3-yne) T-NAD+, requires 
spiking engineered analog-sensitive ARTD enzymes, since it cannot be used as a 
substrate by endogenous enzymes [124]. Moreover, ARTDs inefficiently metabolize 
NAD+ analogues, due to their bulky structure. The use of engineered ARTDs on the 
other side requires KO of the endogenous enzymes, which might perturb cell 
metabolism.  
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1.10. MS-based identification of ADP-ribosylation 
The fragmentation of ADP-ribose was first tested using collision-induced dissociation 
(CID) [1]. Using CID, ADP-ribose fragments and produces characteristic ions (Figure 
5). At the same time, fragmentation of ADP-ribose leads to the complete loss 
 of the modification from the peptide, leading to problems with the acceptor site 
assignment. Moreover, the fragmentation of the ADP-ribosylated peptide backbone 
using CID fragmentation is poor [1].  
Alternatively to CID, electron capture dissociation (ECD) is a mild fragmentation 
method, which does not fragment ADP-ribose [1]. Thus, Hengel et al. proposed to use 
ECD and the later developed electron transfer dissociation (ETD) for the identification 
of ADP-ribosylated acceptor sites with MS/MS [54]. However, the systematic analysis 
of in vitro ADP-ribosylated ARTDs revealed that higher energy collisional 
dissociation (HCD), which was developed after CID, produced better results compared 
to ETD fragmentation [125]. Moreover, ADP-ribose marker ions can be used to tune 
the MS-method to selectively fragment only potentially ADP-ribosylated peptides 
increasing the number of identifications as well as the accuracy of the site assignments 
[125].   
1.11. MS-based quantification methods using a shotgun approach 
Quantitative analysis is critical for understanding PTM function. Protein abundance, 
site occupancy and PTM dynamics in cellular signaling can be addressed by the 
quantification of PTMs [12]. MS-based proteomics were not a quantitative approach 
originally. Different physicochemical properties of proteolytic peptides (size, charge, 
hydrophobicity), introduced substantial differences in their behavior in MS/MS 
measurements [12]. Nevertheless, several approaches were developed to overcome 
these shortcomings and allow quantitative studies. Quantitative MS measurements can 
Figure 5. Fragmentation of ADP-ribose upon CID and HCD fragmentation. The table indicates 
the masses of generated fragments.  Modified from [1].  
23 
 
be performed either using standard shotgun methods or using specially developed 
targeted approaches.  
1.11.1. Stable isotopes labeling methods 
The classical method for shotgun quantification is the use of stable isotopes 
incorporated into peptides. The main principle of this quantification is the stable 
isotope dilution theory. Based on this theory, the endogenous and labeled peptides 
have identical chemical structures and thus identical MS behavior. Since MS allows to 
distinguish mass differences of these peptides, quantification is performed by 
comparing the signal intensities of endogenous and labeled peptides to each other. 
Thus, stable isotope labeling of proteins in combination with a proper enrichment 
technique can enable the relative quantification of PTMs under different experimental 
conditions [126]. 
Protein labeling is achieved either via metabolic labeling in vivo or chemical 
labeling after extraction of proteins. Additionally, stable isotopes can be added after 
sample preparation as internal standards (Figure 6). Metabolic labeling is an in vivo 
labeling method, which allows the labeling of proteins directly in cells by growing 
them in the media containing labeling reagents [127, 128]. The best-known example is 
stable isotope labeling by amino acids in cell culture (SILAC) [129]. Usually, SILAC 
Figure 6. Shotgun MS-based quantification methods. Dashed figures and lines indicate the steps 
when samples are separately processed.  Horizontal lines indicate the steps when samples are 
combined. The star indicates the earliest step where samples can be combined. Label-free samples are 
measured separately, and obtained data is combined during data analysis. Modified from [3]. 
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utilizes radioactively labeled 3C and/or 15N-labeled arginine and lysine. When 
combined with the standard shotgun method using a trypsin digest, which cleaves 
peptides after Ks and Rs, this combination of isotopes enables the labeling of every 
peptide in the mix. However, due to the limited combination of available labeled 
amino acids, SILAC is hard to multiplex. One of the main advantages of metabolic 
labeling methods is that they provide a high measurement accuracy. The fact that the 
samples are combined immediately after the extraction procedure decreases the 
variability introduced by downstream processing steps (e.g. enrichment of PTMs).   
Another approach to achieve isotope labeling is chemical labeling. In these 
methods, peptides are labeled with either light or heavy tags after protein extraction. 
The first developed method was using an Isotope-coded affinity tag (ICAT). ICAT 
uses a radioactively labeled reagent reactive against the cysteine (C) groups of the 
proteins. Additionally, the ICAT reagent contains a biotin-tag that is used to recover 
the labeled peptides using a pulldown with avidin beads [130]. However, the 
application of ICAT is limited to C-containing proteins. Moreover, unspecific 
background binding of avidin affinity purification is common. To overcome these 
drawbacks, several alternative methods like N-terminal labeling [128] and iTRAQ 
[131] were developed.  
In addition to the aforementioned general protein labeling techniques, special 
PTM labeling methods i.e. for phosphoproteins have also been described [132, 133]. 
In contrast to SILAC, chemical labeling methods allow for easier multiplexing. 
However, the high cost of labeling reagents is a general limitation of all techniques 
using isotopes.   
1.11.2. Label-free quantification methods 
The development of instruments, which provide highly accurate and sensitive 
measurements, improved the reproducibility of shotgun measurements. Based on these 
improvements, label-free quantification methods become a valid alternative to 
quantification with labeled standards. An obvious advantage of the label-free approach 
is the simpler sample preparation, making it applicable to the analysis of various 
samples, from in vitro reactions to pathological biopsies [134]. However, the data 
analysis and interpretation should be approached with care due to a potentially high 
variability. Since standards are missing, cross sample variability is not assessed in this 
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type of measurements. Thus, several statistical tools have been developed allowing 
normalization of quantitative data after label-free measurements [135-137].  
1.12. Targeted proteomics approaches 
The main drawback of shotgun proteomics is its rather moderate reproducibility due to 
the data dependency of the MS/MS fragmentation. During the measurement, the 
instrument will select a number “n” (usually n = 10-12) of most abundant precursors 
from the MS spectra on which it will perform MS/MS fragmentation. This selection 
introduces a bias toward the most abundant peptide species. Additionally, dynamic 
exclusion is usually introduced to obtain an increased number of fragmented 
precursors. Applying this parameter, the instrument excludes already fragmented 
precursors from the following MS/MS fragmentations for a given period. Although 
good during the discovery phase, this parameter leads to an imprecise quantification of 
peptides since only a few scans of the same precursors are obtained [138].  
To increase reproducibility of MS-based proteomics, targeted methods were 
developed. The basic principle of this kind of analysis is that the instrument will 
perform an MS/MS scan only on the selected targets. The mass spectrometer will only 
choose the precursors that have a similar m/z and a corresponding elution time of the 
peptide of interest for MS/MS fragmentation. In the targeted method, the precursor is 
monitored and fragmented several times (usually 10-12 times), which enables the 
precise quantification of the precursor [139]. These features enable a wide dynamic 
range and a low limit of detection making the methods well suited for the analysis of 
complex samples[140]. However, method development for targeted proteomics is still 
dependent on shotgun measurements since knowledge of the targets, and their 
fragmentation is essential for validating peptide identifications [138, 141].  
The first targeted method was developed in the 80s and was named multiple 
reaction monitoring (also known as selected reaction monitoring (SRM)). Originally 
established for quantification and chemical structure elucidation of low molecular 
weight components [142], SRM was later adapted for proteomics [143]. SRM 
measurements are performed on triple quadrupole (Q) instruments, where the first 
(Q1) and the last quadrupole (Q3) serve as mass analyzers and the second quadrupole 
(Q2) is a collision cell. The precursor is quantified if the Q1-Q3 transition is similar to 
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the known fragmentation of the targeted peptide. In principle, 3-5 transitions per 
peptide are monitored [144] (Figure 7).  
  
Figure 7. The principle of targeted proteomics methods. The SRM method is performed with QqQ 
and monitors pre-defined transitions (labeled with 1-5). The PRM method is performed with Orbitrap, 
allowing monitoring of all fragment ions from a selected precursor. Modified from [145]. 
The SRM method is an extremely useful tool for PTM quantification since it 
provides the sensitivity and allows the identification of PTMs even in complex 
samples. By optimizing Q1-Q3 transitions, it is possible to specifically target modified 
precursors. E.g., in the case of phosphorylation, targeting can be achieved by 
monitoring the common loss of phosphogroups upon HCD fragmentation [146]. 
Additionally, spiking heavy-labeled standards (analogs to the targeted peptides) allows 
absolute quantification of peptides and PTM sites [147]. However, the method 
development for SRM can be challenging since it is important to identify and validate 
the correct transitions for each targeted precursor to ensure specificity of the assay 
[148].  
PRM measurements are performed on a benchtop quadrupole Orbitrap mass 
spectrometer. In this case, the role of Q3 is conducted by Orbitrap, which provides 
high resolution and high mass accuracy. Orbitrap mass spectrometer operating in PRM 
mode detects all fragment ions coming from the precursor, allowing easier validation 
of the peptide identity [149]. In this case, it is not necessary to pre-define the 
monitored transitions or to know the precise PTM localization site [139]. The 
relatively straightforward method development for PRM measurements led to a fast 
evolution of the technique. The high sensitivity of PRM allows the quantification of 
certain PTMs like ubiquitin in complex mixtures without prior enrichment [150]. 
Moreover, the acquisition of high-resolution spectra is useful for assignment of PTM 
modification sites [151]. 
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2. AIMS OF THE PROJECT 
Despite many efforts and the recent successes from several groups in identifying the 
ADP-ribosylome, a comprehensive understanding of ADP-ribosylation (e.g. 
identification of modified proteins and their acceptor sites as well as their dynamics) 
in oxidative stress remained to be determined. Thus, the goal of this PhD project was 
to develop rapid and highly reproducible MS-based assays for the quantification of 
certain ADP-ribosylated target proteins. The project had three major aims: 
Aim 1: The identification of the oxidative stress-induced ADP-ribosylome. 
Using a shotgun proteomic approach, we aimed at identifying the cellular ADP-
ribosylome and the specific ADP-ribose acceptor sites in oxidative stress. For that, the 
important step was to establish a reliable enrichment method. Additionally, 
optimization of MS/MS parameters specifically tailored for the analysis of ADP-ribose 
acceptor sites with high accuracy was essential.  
Aim 2: The development of quantitative MS-based assays to monitor the relative 
concentrations of ADP-ribosylated proteins under oxidative stress conditions. The 
ADP-ribosylated peptides identified in the previous step were used for the 
development of quantitative methods based on the PRM approach.  
Aim 3: The Confirmation and validation of identified oxidative stress markers in 
different cell types exposed to oxidative stress. The validation aimed to reveal those 
ADP-ribosylated markers that can be reliably used with extracts from various cell lines 
and under different experimental conditions. Considering the important function of 
ADP-ribosylation in oxidative stress, ADP-ribosylation of specific target sites might 
serve as a quantitative sensor for cellular stress. 
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3. RESULTS 
3.1. Overview of a publication 
3.1.1. Proteome-wide identification of the endogenous ADP-ribosylome of mammalian 
cells and tissue 
Authors: Rita Martello1, Mario Leutert1, Stephanie Jungmichel1, Vera Bilan, Sara C. 
Larsen, Clifford Young, Michael O. Hottiger & Michael L. Nielsen 
1 – equal contribution 
Journal: Nature Communications DOI: 10.1038/ncomms12917 
Contribution: I performed in vitro ADP-ribosylation assay with ARTD1 and ARTD10 
(Figure 1D), the trans-modification in vitro ADP-ribosylation assay with ARTD1 and 
potential target candidates (including K-modification site mutants) (Figure 2C), and 
the glycation experiment with MALDI-TOF (Figure S2B and C). 
 
3.2. Overview of submitted manuscripts 
3.2.1. Combining HCD and EThcD fragmentations in a product dependent manner 
provides in-depth characterization of the cellular ADP-ribosylome  
Authors: Vera Bilan1, Mario Leutert1, Paolo Nanni1, Christian Panse and Michael O. 
Hottiger 
1 – equal contribution 
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Supplementary Materials 
 
Supplementary Figure Legends 
 
Supplementary Figure 1  
(a) HCD tandem mass spectrum of peptide sequence GKSGAALSK, identifying Lysine K498 as ADP-
ribosylated acceptor site. Identification of ADP-ribosylated peptides are greatly aided by the diagnostic 
ions generated by the ADP-ribosylation group of the modified peptide (Labeled as “Ribose”, 
“Adenosine”, “AMP”, “ADP”, “-ADPR”, “-ADP”, “-AMP”, “-Adenosine”. 
(b) Distribution of identified ADP-ribosylation sites per protein 
(c) ETD tandem mass spectrum of peptide sequence GKSGAALSK, idenfying Lysine K498 as ADP-
ribosylated acceptor site. Further corroborating the ability of HCD for mapping of ADP-ribosylation 
sites. 
(d) ETD tandem mass spectrum of peptide sequence LPVSSKPGK. 
(e) Abundance distribution of the human HeLa proteome (white bars); the distribution of the annotated 
human nuclear HeLa proteome (red bars); and the distribution of identified ADP-ribosylated factors 
(blue bars). 
 
Supplementary Figure 2 
(a) Experimental design of SILAC experiment to determine if PARG digestion is able to induce in vitro 
glycation. Briefly, heavy labeled SILAC cells were treated with purified PAR while light SILAC cells 
were left untreated. Both cell conditions were subsequently treated with PARG, mixed 1:1 and ADP-
ribosylated peptides analysed by LC-MS/MS. If PARG digestion is able to cause in vitro glycation we 
would expect identification of SILAC regulated ADP-ribosylation sites. 
(b) In vitro glycation analysis of H2B peptide sequence PQPAKSAPAPKKG at different time-points 
and pH.  
(c) Tandem mass spectrum that map in vitro glycations products to lysine residues within the 
investigated H2B peptide, PQPAKSAPAPKKG. 
 
Supplementary Figure 3 
In vitro PARylation analysis of identified protein targets FEN1, CEBPB and SSRP1. Various inactive 
mutant versions of purified full-length human ARTD1 (Y907A, C908R or E988K) was incubated with 
recombinantly expressed proteins in the presence of 32P-NAD and double-stranded DNA oligomer. 
Samples were resolved by SDS-PAGE, stained with Coomassie (CB; lower panels) and 32P-
incorporation was detected by autoradiography (P32; upper panels). 
For all investigated PARP1 mutants no ADP-ribosylation was detected, confirming that the ADP-
ribosylation observed (Figure 2c) is catalyzed by wild-type PARP1 and not a glycation product. 
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Supplementary Figure 4 
(a) Experimental design used for quantitative evaluation of ADP-ribosylation sites (SILAC ratios). 
Light SILAC condition was exposed shortly to H2O2 while heavy SILAC was exposed as indicated. A 
quantitative analysis revealed that measured SILAC ratios are most increased following 5-10 
stimulation with H2O2. 
(b) Immunoflourescence (IF) imaging of cells treated with H2O2 for indicated time-points (0 min, 5 min, 
10 min, 30 min, 1 hour, 2 hours), and immunostained with PAR-specific antibody or DAPI as indicated. 
Strongest PAR signal is observed after 5-10 minute treatment of H2O2. 
(c) Left: Immuno-slot blot analysis of PAR formation in HeLa cells treated with H2O2 for indicated 
time-points (0 min, 5 min, 10 min, 30 min, 1 hour, 2 hours). Right: Strongest PAR signal is observed 
after 5-10 minute treatment of H2O2. 
B) Densiometric evaluation of immune-slot blot analysis. The strongest abundance in PAR signal is 
observed after 5-10 minutes treatment of H2O2. Data represent mean +/- SD of n=3 independent 
analyses. 
(d) Distribution of ADP-ribosylation occupancy in cells exposed to H2O2 for 10 minutes. Fifty percent 
of all ADP-ribosylation sites have occupancy of 11% or more. 
(e) Distribution of amino acid occupancies across identified ADP-ribosylation sites in cells exposed to 
H2O2 for 10 minutes. Occupancy is determined for both heavy (Blue bars) and light (Red bars) SILAC 
conditions, which correspond to treated and untreated conditions, respectively. Collectively arginine 
residues are observed harboring the highest occupancy. 
(f) Venn diagram between identified ADP-ribosylated substrates and previously identified PARylated 
substrates derived from Jungmichel et al, 2013. 
(g) Scatter plot show correlation of logarithmized H/L ratios from Olaparib treated SILAC experiments 
as indicated. 
 
Supplementary Figure 5 
(a) Protein interaction networks of regulated ADP-ribosylation sites upon Olaparib treatment. Data was 
combined from two SILAC experiments where cells were treated with two different inhibitor 
concentrations (1 µM and 10 µM Olaparib). Network interaction data was extracted from the STRING 
database and visualized using Cytoscape. 
(b) GO functional annotation of significantly regulated proteins from Olarapib SILAC experiments as 
compared to annotated GO genes in the entire genome (indicated p-values < 1.5e-17). Strong 
enrichment for biological processes known to be targeted by PARP is observed. 
(c) GO biological processes annotation of tissue-derived ADP-ribosylation factors compared to 
annotated GO genes across the entire human genome. 
(d) KEGG pathway annotation of tissue-derived ADP-ribosylation factors compared to annotated genes 
across the entire human genome. 
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Supplementary Figure 6 
(a) Venn diagram showing the overlap in identified proteins from analyzing Af1521 enrichment 
samples with HCD versus ETD (comparison of data listed in Supplementary Data 1 and Supplementary 
Data 5). 
(b) Uncropped western blots from Fig. 2d. 
 
Supplementary Note 1 - Estimation of enrichment level 
In order to establish a proper lysates:Af1521 level, we incubated a fixed amount of purified Af1521 
macrodomain with increasing amounts of a H2O2-treated HeLa lysates (2.5 mg, 5 mg, 10 mg, 15 mg, 
20 mg of lysate material, respectively). Following incubation and Af1521 enrichment, we determined 
the number of identified ADP-ribosylation sites by LC-MS analysis (Figure a). From replicate analyses 
we observed an increasing amount of identified ADP-ribosylation sites with increasing levels of HeLa 
lysate. However, a saturation level was observed at levels above 10 mg of cell lysates (Figure a), 
indicative of saturation of the Af1521 domain. Hence, from these data we determined that the 
appropriate amount of cell lysate material for our enrichment procedure would be 8-10 mg. 
 
 
Figure a 
To estimate the enrichment level of the developed methodology, we compared the number of identified 
ADP-ribosylation sites from a non-enriched HeLa cell lysate to the same sample after enrichment with 
our Af1521 methodology. Both samples were initially treated with 500 µM H2O2 to induce formation of 
ADP-ribosylation, and subsequently both samples were treated with PARG enzyme to convert all PAR 
into MAR.  
However, in the next step, only one lysate sample was used for enrichment of ADP-ribosylation sites 
using the Af1521 macrodomain while the other whole HeLa cell lysate was left non-enriched. Both 
samples were subsequently analyzed by LC-MS using identical LC gradient and MS settings, and the 
obtained data files were processed for identification of ADP-ribosylation sites using the MaxQuant 
software suite (see method section for further details and settings). 
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From the LC-MS analysis of the non-enriched whole HeLa lysate (a total of 500 ng lysate was loaded 
onto the LC column) we identified only a single (1) ADP-ribosylation site, which is in stark contrast to 
the >500 ADP-ribosylation sites identified using the Af1521 enrichment methodology under identical 
LC-MS settings (similar LC gradient length and MS acquisition method). To compare this to another 
PTM, we additionally searched the non-enriched whole HeLa lysate for phosphorylations from which 
we identified 70 high-confident phosphorylation sites (all with localization score >0.75). From these 
data we conclude our Af1521 methodology entails an enrichment level of minimum 500.  
  
 Total peptides ADP-ribosylated 
peptides 
Phosphorylated 
peptides 
500 ug whole HeLa cell lysate ~25,000 1 70 
Af1521 enrichment – 2.5mg 15,814 244 - 
Af1521 enrichment – 5mg 19,122 395 - 
Af1521 enrichment – 10mg 19,039 433 - 
Af1521 enrichment – 15mg 18,484 526 - 
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SUPPORTING INFORMATION 
 
Table S1: Overview of the evaluated MS/MS methods. 
Table S2: Identified ADP-ribosylated peptides with K motif and corresponding protein IDs. 
Figure S1: MS/MS fragmentation of ADP-ribosylated peptides. 
Figure S2: Physicochemical characteristics of identified ADP-ribosylated peptides identified with HCD, ETcaD and 
EThcD fragmentations.  
Figure S3: EThcD Fragmentation of a dual-modified peptide.  
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Table S1: Overview of the evaluated tandem mass spectrometry methods. 
NCE: Normalized Collision Energy; sa*: supplementary activation; HCD: Higher Energy Collision induced 
dissociation; ETcaD electron transfer dissociation with supplemental collisional activation; EThcD . electron-
transfer/higher-energy collision dissociation; FT: Fourier Transformation; p: profile 
 
Table S2 Protein lists with a presence of K modification motifs 
Motif 1  -----KS---- (motif score 17.29) 
Surrounding Sequence Accession Site Best Ascore 
Localization 
Probability 
AAKGKLKSQNTKP sp|Q8IYA6|CKP2L_HUMAN K30 117.14 100.00% 
NLRSSLKSSLHTL sp|Q13415|ORC1_HUMAN K448 112.68 100.00% 
VVAPRGKSGAALS sp|P09874|PARP1_HUMAN K498 179.49 100.00% 
 MPEPAKSAPAPK sp|P06899|H2B1J_HUMAN K6 54.94 100.00% 
AKEAAGKSSGPTS sp|Q00839|HNRPU_HUMAN K186 125.73 100.00% 
QVSDERKSYSPRK sp|P35251-2|RFC1_HUMAN K280 52.22 100.00% 
VDMNSPKSKKAKK sp|Q9NR30|DDX21_HUMAN K73 30.66 100.00% 
MIKKKTKSSKPSK sp|P35251-2|RFC1_HUMAN K1124 85.19 100.00% 
LVIGDHKSTSHFR sp|O00193|SMAP_HUMAN K62 145.84 100.00% 
LKQRLGKSNIQAR sp|Q9Y3Y2-3|CHTOP_HUMAN K82 121.78 100.00% 
KSDEPKKSVAFKK sp|P07305-2|H10_HUMAN K86 42.69 100.00% 
STRDPVKSQSKSN sp|P46013-2|KI67_HUMAN K2622 54.47 100.00% 
GAATPKKSAKKTP sp|P10412|H14_HUMAN K149 52.22 100.00% 
LSDEFSKSHKSRR sp|Q9BQ39|DDX50_HUMAN K87 39.43 100.00% 
DQEQQLKSAQSPS sp|Q14669-2|TRIPC_HUMAN K123 60.43 100.00% 
LQRAPLKSVGPDF sp|P78527|PRKDC_HUMAN K2694 87.44 100.00% 
GAALSKKSKGQVK sp|P09874|PARP1_HUMAN K506 41.83 100.00% 
MPEAAVKSTANKY sp|P51858|HDGF_HUMAN K39 66.24 100.00% 
MS Method Description 
Fragmentation events 
Cycle 
Time 
(sec) 
Data 
collection  
(MS1/ 
MS/MS) 
MS/MS scans 
m/z 
product 
ions (n≥1) 
FT preview FT Reagent 
 
HCD ETcaD EThcD 
  
AGC 
Target 
injection 
time 
(ms) 
NCE 
(%) 
AGC 
Target 
injection 
time 
(ms) 
NCE 
(%) 
AGC 
Target 
injection 
time 
(ms) 
NCE 
(%)  
a HCD 
only HCD 
MS/MS 
X - - 3 FT, p - - - 500000 240 35 - -   - 
b ETcaD 
only ETcaD 
MS/MS 
- X - 3 FT, p - - - 500000 240 - 
calibrated ETD 
parameters, with sa* 
(NCE 20)  
- 
c EThcD 
only EThcD 
MS/MS 
- - X 3 FT, p - - - 500000 240 - 
calibrated ETD 
parameters, with sa* 
(NCE 25)  
- 
d 
HCD-PD-
EThcD 
HCD product 
dependent 
EThcD 
X - X 3 FT, p - - - 500000 240 35 
calibrated ETD 
parameters, with sa* 
(NCE 25)  
1
36.0623; 
250.094; 
348.0709; 
428.037 
e 
HCD-PP-
HCD/EThcD 
HCD product 
preview 
HCD-EThcD 
X, X - X 3 FT, p 50000 60 38 500000 240 35 
calibrated ETD 
parameters, with sa* 
(NCE 25)  
1
36.0623; 
250.094; 
348.0709; 
428.037 
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GSTNYGKSQRRGG sp|Q99729-3|ROAA_HUMAN K271 46.99 100.00% 
LDAAPGKSQKRKY sp|Q9NVU7-2|SDA1_HUMAN K477 36.58 100.00% 
PAKNAQKSNQNGK sp|P06748|NPM_HUMAN K206 67.18 100.00% 
KDVADYKSKGKFD sp|O15347|HMGB3_HUMAN K161 21.56 100.00% 
PPKTFEKSMMNLQ sp|P11387|TOP1_HUMAN K642 65.93 100.00% 
KPKVPLKSAPPPM sp|Q68D10-2|SPT2_HUMAN K161 146.11 100.00% 
LWERNIKSHLGNV sp|Q8WW12|PCNP_HUMAN K167 1,000.00 100.00% 
QSVSQNKSYLAVR sp|Q9UMY1|NOL7_HUMAN K170 74.94 100.00% 
 MPEPTKSAPAPK sp|P58876|H2B1D_HUMAN K6 58.97 100.00% 
 MPEPSKSAPAPK sp|P33778|H2B1B_HUMAN K6 51.08 100.00% 
PPKPRLKSGGGFG sp|Q9H4L4|SENP3_HUMAN K43 125.55 100.00% 
ASIISLKSDKKRK sp|Q9H0A0|NAT10_HUMAN K989 43.02 100.00% 
GKKSGKKSYLSGG sp|P25490|TYY1_HUMAN K183 165.44 100.00% 
KKSNKNKSGKNQF sp|Q00839|HNRPU_HUMAN K694 57.6 100.00% 
YSPERSKSYSFHQ sp|Q8NEY8-2|PPHLN_HUMAN K167 144.15 100.00% 
KEEGINKSEKRMK sp|P09874|PARP1_HUMAN K518 39.54 100.00% 
INLLPSKSSVTKI sp|Q9ULW0|TPX2_HUMAN K357 37.15 100.00% 
 MPEPVKSAPVPK sp|Q99879|H2B1M_HUMAN K6 70.69 100.00% 
LKFTKGKSFRHEK sp|Q14978-2|NOLC1_HUMAN K678 81.07 100.00% 
 MPDPAKSAPAPK sp|P23527|H2B1O_HUMAN K6 41.7 100.00% 
LKFTKGKSFRHEK sp|Q14978-3|NOLC1_HUMAN K669 81.07 100.00% 
RTPRRSKSDGEAK sp|P26358|DNMT1_HUMAN K142 53.57 100.00% 
LKAVTQKSSNSLV sp|Q99575|POP1_HUMAN K125 194.76 100.00% 
EQRRELKSAGGLM sp|Q9UNQ2|DIM1_HUMAN K23 69.08 100.00% 
GGATPKKSAKKTP sp|P16403|H12_HUMAN K149 52.22 100.00% 
ENYRRNKSYSFIA sp|Q8IWX8|CHERP_HUMAN K901 141.33 100.00% 
Motif 2 ----KS----K (motif score 35.87) 
Surrounding Sequence Accession Site Best Ascore 
Localization 
Probability 
 MPEPAKSAPAPK sp|P06899|H2B1J_HUMAN K6 54.94 100.00% 
QVSDERKSYSPRK sp|P35251-2|RFC1_HUMAN K280 52.22 100.00% 
VDMNSPKSKKAKK sp|Q9NR30|DDX21_HUMAN K73 30.66 100.00% 
MIKKKTKSSKPSK sp|P35251-2|RFC1_HUMAN K1124 85.19 100.00% 
KSDEPKKSVAFKK sp|P07305-2|H10_HUMAN K86 42.69 100.00% 
GAALSKKSKGQVK sp|P09874|PARP1_HUMAN K506 41.83 100.00% 
PAKNAQKSNQNGK sp|P06748|NPM_HUMAN K206 67.18 100.00% 
 MPEPTKSAPAPK sp|P58876|H2B1D_HUMAN K6 58.97 100.00% 
 MPEPSKSAPAPK sp|P33778|H2B1B_HUMAN K6 51.08 100.00% 
ASIISLKSDKKRK sp|Q9H0A0|NAT10_HUMAN K989 43.02 100.00% 
KEEGINKSEKRMK sp|P09874|PARP1_HUMAN K518 39.54 100.00% 
 MPEPVKSAPVPK sp|Q99879|H2B1M_HUMAN K6 70.69 100.00% 
LKFTKGKSFRHEK sp|Q14978-2|NOLC1_HUMAN K678 81.07 100.00% 
 MPDPAKSAPAPK sp|P23527|H2B1O_HUMAN K6 41.7 100.00% 
LKFTKGKSFRHEK sp|Q14978-3|NOLC1_HUMAN K669 81.07 100.00% 
RTPRRSKSDGEAK sp|P26358|DNMT1_HUMAN K142 53.57 100.00% 
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Motif 3 ----SK----- (motif score 6.14) 
Surrounding Sequence Accession Site Best Ascore 
Localization 
Probability 
FQLFLSKVEETFQ sp|Q96T88-2|UHRF1_HUMAN K730 65.84 100.00% 
VADYKSKGKFDGA sp|O15347|HMGB3_HUMAN K163 39.54 100.00% 
AAQAKSKQAILAA sp|O60869|EDF1_HUMAN K25 127.41 100.00% 
TASKASKEKTPSP sp|Q9H1E3|NUCKS_HUMAN K199 64.45 100.00% 
LSDEFSKSHKSRR sp|Q9BQ39|DDX50_HUMAN K87 39.43 100.00% 
SGAALSKKSKGQV sp|P09874|PARP1_HUMAN K505 25.23 100.00% 
ADDIKSKKKREQS sp|P45973|CBX5_HUMAN K104 25.23 100.00% 
GRPTASKASKEKT sp|Q9H1E3|NUCKS_HUMAN K196 53.06 100.00% 
SQPLASKQEKDGT sp|P17096-2|HMGA1_HUMAN K15 69.08 100.00% 
AAATSSKTPS    sp|Q9UNZ5|L10K_HUMAN K96 129.75 100.00% 
SQPLASKQEKDGT sp|P17096-3|HMGA1_HUMAN K15 69.08 100.00% 
MNSPKSKKAKKKE sp|Q9NR30|DDX21_HUMAN K75 20.98 99.90% 
ALSKKSKGQVKEE sp|P09874|PARP1_HUMAN K508 174.88 100.00% 
KKTKSSKPSKPEK sp|P35251-2|RFC1_HUMAN K1127 61.26 100.00% 
 MPEPSKSAPAPK sp|P33778|H2B1B_HUMAN K6 51.08 100.00% 
YSPERSKSYSFHQ sp|Q8NEY8-2|PPHLN_HUMAN K167 144.15 100.00% 
INLLPSKSSVTKI sp|Q9ULW0|TPX2_HUMAN K357 37.15 100.00% 
RTPRRSKSDGEAK sp|P26358|DNMT1_HUMAN K142 53.57 100.00% 
VTSKKSKGESDDF sp|P11388-2|TOP2A_HUMAN K1518 39.54 100.00% 
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Figure S1: MS/MS fragmentation of ADP-ribosylated peptides. 
A) Fragmentation pattern of ADP-ribose upon HCD fragmentation.  B) Distribution of ADP fragment ions in 
MS/MS spectra from HCD fragmentation. Only spectra containing at least two indicative ions with relative 
intensity of at least 10% of total spectra intensity were considered. C) Fragmentation of ADP-ribosylated peptides 
in HCD (upper panel) and EThcD (lower panel). Spectra for D, E, and R sites are shown. The position of 
modification is indicated in red. Presented spectra were deconvoluted, and precursor peak was excluded from the 
analysis. D) The coverage ratio of the fragmented precursors in each fragmentation method. The ratio was 
calculated as the number of assigned fragment ions normalized to the length of the peptide.  
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Figure S2: Physicochemical characteristics of identified ADP-ribosylated peptides identified with HCD, ETcaD and 
EThcD fragmentations. PSMs containing ADP-ribosylation were used for the analysis. The values are normalized 
over total ADP-ribosylated PSMs count for each fragmentation method. A) Distribution of charge states for ADP-
ribosylated precursors identified with HCD, ETcaD, and EThcD. B) Peptide length distribution for ADP-
ribosylated precursors identified with HCD, ETcaD, and EThcD. C) Basic/acidic properties of peptides were 
evaluated by the presence of acidic (D, E) and basic amino acids (K, R, H) in the sequence.  
 
 
 
Figure S3: EThcD Fragmentation of a dual-modified peptide. Characteristic ion carrying both modification sites 
(c(14)) and c2 ion characteristic for the K site are indicated in red square.  The position of modification is indicated 
in red. Presented spectra were deconvoluted, and precursor peak was excluded from the analysis. 
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Summary/Abstract 
Protein ADP-ribosylation is a covalent, reversible post-translational modification 
(PTM) catalyzed by ADP-ribosyltransferases (ARTs). Proteins can be either mono- or 
poly-ADP-ribosylated under a variety of physiological and pathological conditions. To 
understand the functional contribution of protein ADP-ribosylation to normal and 
disease/stress states, modified protein and corresponding ADP-ribose acceptor site 
identification is crucial. Since ADP-ribosylation is a transient and relatively low 
abundant PTM, systematic and accurate identification of ADP-ribose acceptor sites 
has only recently become feasible. This is due to the development of specific ADP-
ribosylated protein/peptide enrichment methodologies, as well as technical advances 
in high accuracy liquid chromatography - tandem mass spectrometry (LC-MS/MS). 
The standardized protocol described here allows the identification of ADP-ribose 
acceptor sites in in vitro ADP-ribosylated proteins and will, thus, contribute to the 
functional characterization of this important PTM. 
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IMAC enrichment, phosphoenrichment 
1. Introduction 
Protein ADP-ribosylation is a covalent post-translational modification (PTM) catalyzed 
by different ADP-ribosyltransferases (ARTs). These enzymes use nicotinamide 
adenine dinucleotide (NAD+) as a substrate to transfer the ADP-ribose (ADPr) moiety 
onto specific amino acid side chains, a process termed protein mono-ADP-
ribosylation (MARylation). ARTs can also mediate poly-ADP-ribosylation (PARylation) 
by transferring the ADPr moiety onto an existing protein-bound ADP-ribose unit. 
Currently, 22 cellular human ARTs are known. They are subdivided into ARTCs (C for 
C2/C3 toxin-like) and ARTDs (D for diphtheria toxin-like, also called PARPs). While 
ARTCs are membrane-associated or secreted ARTs, human ARTDs form a family of 
18 intracellular enzymes with confirmed or putative mono- or poly-ADP-
ribosyltransferase activity (1-3).  
Several enzymes that remove ADP-ribose from mono- and poly-ADP-ribosylated 
substrates have also been identified, rendering ADP-ribosylation a fully reversible 
PTM. Several mammalian ADP-ribosylhydrolases have been characterized so far, 
including poly-ADP-ribose glycohydrolase (PARG), ADP-ribosylhydrolase 3 (ARH3), 
both of which are able to hydrolyze poly-ADP-ribose, and the mono-ADP-
ribosylarginine hydrolase 1 (ARH1). In addition, the macrodomain-containing proteins 
MacroD1, MacroD2 and C6orf130 have recently also been shown to exhibit mono-
ADP-ribosylhydrolase activity (4-6). 
To elucidate the functional role of protein ADP-ribosylation, systematical analysis of 
all ADP-ribosylated proteins and identification of their ADP-ribose acceptor sites is 
necessary. Comparable to many other PTMs, the fraction of ADP-ribosylated cellular 
proteins is very low. Thus, studying this group of modified proteins requires specific 
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ADP-ribosylated protein/peptide enrichment methodologies. Mass spectrometry (MS)-
based proteomics is probably the most powerful tool for the analysis of PTMs. 
However, the analysis of this PTM has proven to be very challenging for several 
reasons, including the highly transient nature and the low abundance of ADP-
ribosylated proteins, the special physicochemical properties of the PTM (bulky, highly 
charged, heterogeneous structure, labile) and the number of different amino acids 
that were reported to be modified (acidic and basic amino acids with a primary amino 
group on the side chain) (7). Characterization of ADP-ribose acceptor sites by MS has 
significantly improved following the development of high-resolution mass 
spectrometers and novel fragmentation techniques.  
In the past few years, several methods for the identification of ADP-ribose acceptor 
sites on in vitro and in vivo ADP-ribosylated proteins have been published. Zhang et 
al. (8) established an enrichment protocol based on the isolation of ADP-ribosylated 
peptides by boronate affinity chromatography and subsequent modified peptide 
elution using hydroxylamine (NH2OH). This methodology leaves a characteristic mass 
signature of 15.01 Da at the ADP-ribose acceptor site (8). A major drawback of this 
protocol is that the chemical reaction employed here limits the detection of ADP-
ribosylated amino acids to glutamates and aspartates only. Other groups have also 
used boronate affinity enrichment, but in combination with acidic elution, which leaves 
the ADP-ribose moiety intact and leads to a release of all bound peptides. This, 
unfortunately, resulted in high background of unmodified peptides. Additionally, 
hydroxylamine treatment has also been used as a stand-alone procedure without any 
enrichment but this method only seems useful for strongly ADP-ribosylated targets 
(9,10).  
Phosphoproteomic approaches were also found to co-enrich ADP-ribosylated 
peptides, and protocols have been optimized for the specific enrichment of ADP-
ribosylated or phosphoribosylated peptides (11-14). Chapman et al. (13) and Daniels 
et al. (14) used phosphodiesterases to reduce the mono- and poly-ADP-ribosylation 
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modification (MAR or PAR, respectively) to a protein-bound phosphoribose. The 
resulting phosphoribosylated peptides are subsequently enriched using either Fe(III)-
immobilized metal ion affinity chromatography (IMAC) or TiO2 microspheres. The 
conversion of protein bound MAR or PAR to phosphoribose leads to a detectable 
mass signature of 212.01 Da.  
The most recent enrichment approach published by Martello et al. (15) makes use of 
PARG enzymatic treatment to convert in vivo PARylated peptides into MARylated 
peptides, which are subsequently enriched by the ADP-ribose binding protein AF1521 
and described in chapter XX of this book. This technique allows the accurate and 
reproducible identification of ADP-ribose acceptor sites in vivo. However, this 
enrichment strategy has so far not been tested or optimized for in vitro modified 
proteins.  
Here, we thus describe an updated protocol using a Ti4+-IMAC enrichment based on 
the work done by Chapman et al (13) and Daniels et al (14) to map ADP-ribose 
acceptor sites on in vitro ADP-ribosylated proteins. This protocol is more readily 
applicable to a variety of different samples than the boronate affinity chromatography 
based protocol described by our group in the previous edition of this book for in vitro 
modified proteins (9). More importantly, this new methodology is not biased against 
specific ADP-ribose acceptor sites. The problem that phosphorylated peptides might 
co-enrich with phosphoribosylated/ADP-ribosylated peptides and interfere with the 
sensitivity of the detection is not an obstacle due to the low complexity of in vitro 
modified samples. 
 
2. Materials 
2.1 ADP-ribosylation assay and PARG treatment 
1. hARTD1 is expressed and purified from insect cells as carboxyl-terminal His-
tagged protein and stored in liquid nitrogen.  
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2. hPARG is expressed and purified from insect cells as carboxyl-terminal His-tagged 
protein and stored in liquid nitrogen (see note 1). 
3. 10 mM β-Nicotinamide adenine dinucleotide (NAD+) hydrate >99% (Sigma–Aldrich) 
in Milli-Q water is stored at −20°C. 
4. 10 mM PJ-34 hydrochloride hydrate ≥98% (Sigma-Aldrich) in Milli-Q water is stored 
at -20°C.  
5.ADP-ribosylation buffer (always prepare freshly): 50 mM Tris–HCl pH 8.0, 4 mM 
MgCl2, 250 µM DTT, cOmplete™ EDTA-free Protease Inhibitor Cocktail.  
2.2 FASP Trypsin Digestion 
1. 5x disulfide bond reduction buffer: 250 mM DTT, 250 mM Tris-HCl pH 8.2, 5 M 
urea.  
2. 0.5 ml Microcon 30kDa centrifugal filter units with Ultracel-30 membranes 
(Millipore, MRCF0R030). 
3. Urea buffer: 8 M urea in 50 mM Tris-HCl pH 8.2. 
4. Iodoacetamide solution: 0.05 M iodoacetamide in urea buffer (kept protected from 
light).  
5. 0.5 M NaCl. 
6. 0.05 M ammonium bicarbonate (prepare freshly).  
7. Sequencing grade modified trypsin (Promega).  
2.3 ADP-ribosylated Peptide Enrichment 
1. MagReSyn® Ti4+-IMAC from ReSyn Biosciences. 
2. 70% ethanol. 
3. Loading Buffer: 1 M glycolic acid in 80% acetonitrile.  
4. Wash buffer: 80% acetonitrile and 0.1% acetic acid in H2O.  
5. Elution buffer: 50 mM Tris-HCl pH 8, 10 mM diammonium hydrogen phosphate, 5% 
acetonitrile. 
2.4 Stage Tip Desalting 
1. C18 Empore High performance extraction disks (3M). 
2. 100% methanol. 
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3. Stage Tip Solution A: 0.5% acetic acid in H2O. 
4. Stage Tip Solution B: 80% acetonitrile and 0.5% acetic acid in H2O. 
5. Stage Tip Elution Solution: 60% acetonitrile and 0.5% acetic acid in H2O. 
2.5 Mass Spectrometry 
1. HPLC solvent A: H2O containing 0.1% formic acid. 
2. HPLC solvent B: Acetonitrile containing 0.1% formic acid.  
3. Frit column (inner diameter 75 µm, length 15 cm) packed with reversed phase 
material (C18-AQ, particle size 1.9 μm, pore size 120 Å, Dr. Maisch GmbH, 
Germany). 
4. Instrumentation: Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific, San 
Jose, CA), connected to an Easy-nLC 1000 HPLC system (Thermo Scientific). See 
(see note 2).  
 
3. Methods 
3.1 Overview of the protocol 
In vitro auto- and especially trans-ADP-ribosylation reactions are often not efficient 
and lead to a low abundance of ADP-ribosylated proteins. We, therefore, recommend 
in vitro ADP-ribosylated peptide enrichment following a previously described 
phosphoenrichment technique that is based on immobilized titanium ion affinity 
chromatography (16). This protocol facilitates modified peptide enrichment and 
increases the possibilities of a successful analysis, including ADP-ribosylation site 
determination. In vitro reactions should be carried out according to the optimized 
protocols for the different ADP-ribosyltransferases. The original protocol used 
phosphodiesterases to reduce mono- and poly-ADP-ribosylation modifications (MAR 
or PAR, respectively) to a protein-bound phosphoribose and to enrich subsequently 
phosphoribosylated peptides. We have, however, found that treatment of ADP-
ribosylated proteins with poly(ADP-ribose) glycohydrolase (PARG), which reduces the 
complexity of PAR to protein bound mono-ADP-ribose, works very reliable and allows 
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efficient ADP-ribose enrichment. PARG-treated proteins are further digested with 
trypsin using filter-aided sample preparation (FASP) protocol (17). The ADP-
ribosylated peptides are finally enriched with magnetic microspheres with chelated 
Ti4+ ions. This protocol is optimized to use only very mild buffers for the binding, 
washing and peptide elution steps in order to preserve the ADP-ribose and its linkage 
to the modified amino acid residue. Samples are desalted using a C18 Stage Tip 
protocol (18) and analyzed on an Orbitrap Fusion Tribrid mass spectrometer. HCD 
fragmentation has previously been shown to lead to reproducible identification of 
ADP-ribosylated peptides and this method allows the accurate identification of the 
modified amino acid (19). Mascot searches are performed to identify ADP-ribose 
acceptor sites by setting ADP-riboslyation as a variable modification for lysine, 
arginine, glutamate and aspartate. A representative, annotated spectrum of an 
identified ADP-ribosylated ARTD1 peptide after the Ti4+ IMAC enrichment and the 
HCD ADP-ribose fragmentation pattern are shown in Figure 1.  
 
3.2 ADP-ribosylation assay and PARG treatment 
1. For in vitro auto ADP-ribosylation of ARTD1, incubate 20 pmol hARTD1 in the 
presence of 10 pmol annealed double-stranded oligomer (5-GGAATTCC-3) and 100 
nM NAD+ in ADP-ribosylation buffer (see note 3). Reaction volume: 50 µl, reaction 
conditions: 15 min, 30°C. Terminate the reactions by adding PJ-34 (ADP-ribosylation 
inhibitor) to a final concentration of 10 µM. To generate larger amounts of modified 
target protein, several reactions can be run in parallel (see note 4).  
2. To reduce the complexity of PAR and generate MARylated proteins, samples are 
incubated with 5 pmol hPARG. Adjust the MgCl2 and NaCl buffer concentrations to 10 
mM and 50 mM, respectively, and incubate for 1 h at 37°C. 
3. For the identification of ADP-ribose acceptor sites in peptides proceed immediately 
with the FASP trypsin digestion or, alternatively, freeze the proteins at -20°C.  
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3.3 FASP Trypsin Digestion 
1. Add 5x reduction buffer to the protein sample to achieve 1x and incubate at 37°C 
for 30 min to reduce the disulfide bonds.  
2. Load up to 250 µl of reduced sample onto the Microcon-30kDa centrifugal filter 
unit. Centrifuge at 14’000xg for ~15-20 min at room temperature (RT). Repeat until 
the sample is completely loaded onto the filter. 
3. Add 200 µl of urea buffer to the filter unit. Centrifuge at 14’000xg for ~20 min at RT. 
4. Add 100 µl iodoacetamide solution to the filter unit. Gently shake for 5 min and 
centrifuge at 14’000xg for ~15-20 min at RT. 
5. Add 100 µl of 0.5 M NaCl to the filter unit. Centrifuge at 14’000xg for ~15-20 min at 
RT. Repeat step once. 
6. Add 100 µl of ammonium bicarbonate solution to the filter unit. Centrifuge at 
14’000xg for ~15-20 min at RT. Repeat step twice. 
7. Transfer the filter units to new collection tubes. 
8. Add 120 µl of trypsin (1:25 trypsin to protein), dissolved in ammonium bicarbonate 
solution, to the filter unit and gently shake for 1 min. 
9. Incubate the filter units at RT overnight in a humidity chamber. 
10. The next day, centrifuge the filter units at 14’000xg for ~15-20 min. The flow-
through contains the digested proteins.  
11. Re-elute the column with 80 µl of ammonium bicarbonate solution. 
12. Dry the eluted peptides in a vacuum concentrator (see note 5). 
 
 
3.4 Enrichment of ADP-ribosylated Peptides 
1. Thoroughly resuspend MagReSyn® Ti4+-IMAC microspheres to ensure 
homogeneous suspension. 
2. Transfer 25 µl (0.5 mg) MagReSyn® Ti4+-IMAC to a 2 ml microcentrifuge tube. 
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3. Place the tube on a magnetic separator, allow 10 s for the microspheres to clear, 
and discard the storage solution. 
4. Wash the microspheres, with gentle agitation, in 200 µl of 70% ethanol for 5 min. 
5. Place the tube on the magnetic separator and allow the microspheres to clear. 
Discard the ethanol solution. 
6. Repeat steps 4 & 5. 
7. Add 50 µl loading buffer to microspheres, and let stand for 60 s to equilibrate. 
8. Place the tube on the magnetic separator and allow the microspheres to clear. 
Remove the loading buffer. Important: The microspheres equilibration step should be 
performed immediately before sample loading. 
9. Repeat the equilibration process two additional times.  
10. Mix dried protein digests with 100 µl of loading buffer and add mixture to the 
equilibrated microsphere pellet (see note 6).  
11. Incubate at room temperature for 30 min with continuously shaking to ensure 
adequate sample and microsphere interaction.  
12. Place the tube on the magnetic separator and allow the microspheres to clear. 
Discard the coupling supernatant. 
13. Remove unbound sample by washing microspheres with 100 µl loading buffer for 
30 s with gentle agitation. 
14. Place the tube on a magnetic separator and allow 10 s for the microspheres to 
clear. Remove the supernatant. 
15. Remove non-specifically bound peptides by resuspending the microspheres in 
100 µl wash buffer for 2 min with gentle agitation. 
16. Place the tube on a magnetic separator and allow 10 s for the microspheres to 
clear and remove the supernatant. 
17. Repeat steps 15&16 twice for a total of three washes. 
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18. Elute the bound peptides from the microspheres by adding 60 µl elution buffer 
and letting stand for 15 min. Ensure that the microspheres remain in suspension by 
gently agitating the tube. 
19. Place the tube on the magnetic separator and allow the microspheres to clear. 
Remove the eluate and transfer it to a new tube. 
20. Repeat the elution steps 18&19 twice for a final elution volume of 180 µl.  
 
3.5 Stage Tip Desalting  
1. Prepare StageTips by plugging 2 C18 disks in a 200 µl pipette tip (see note 7).  
2. Make a hole in the lid of a 1.5 ml Eppendorf tube and fit stage tip in. The tip should 
be tightly attached to the lid and the tip should not touch the bottom of the tube. 
3. Activate the Stage Tip by adding 200 μl 100% methanol to the stage tip, centrifuge 
at 1,000 x g for approx. 3 min. 
4. Add 200 μl Stage Tip Solution B to the stage tip, centrifuge at 1,000 x g for approx. 
3 min. 
5. Add 200 μl Stage Tip Solution A to the stage tip, centrifuge at 1,000 x g for approx. 
3 min. 
6. Add 200 μl of your peptide sample, centrifuge at 1,000 x g for approx. 3 min. 
Repeat step until the whole sample is loaded. 
7. Wash Stage Tip by adding 50 μl of Stage Tip Solution A, centrifuge at 1,000 x g for 
approx. 3 min until Stage Tip is completely dry. 
8. Elute Stage Tip by adding 20 μl of Stage Tip Elution solution, centrifuge at 1000 x g 
for approx. 1 min. Repeat elution step once more and combine elutions. 
9. Partially dry the eluted samples in a vacuum concentrator (see note 5). The 
samples can be stored at -20°C or directly proceed by LC-MS/MS. 
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3.6 LC-MS/MS 
All data are acquired on an Orbitrap Fusion Tribrid mass spectrometer connected to 
an Easy-nLC 1000 HPLC system (see note 2). 4 µl of peptide sample in 0.1 % formic 
acid are loaded and separated at a flow rate of 300 nl per min. The following LC 
gradient was applied: 0 min: 2% HPLC solvent B, 60 min: 30% B, 70 min: 97% B, 80 
min: 97% B.  
Survey scans were recorded in the Orbitrap mass analyzer in the range of m/z 350-
1800, with a resolution of 120’000 and a maximum injection time of 50 ms. Higher 
energy collisional dissociation (HCD) spectra were acquired in the Orbitrap mass 
analyzer. A maximum injection time of 240 ms, an AGC target value of 5e5, and a 
resolution of 120’000 were used. The precursor ion isolation width was set to m/z 2.0, 
and the normalized collision energy was 35%. Charge state screening was enabled, 
and charge states 2-5 were included. The threshold for signal intensities was 5e4, 
and precursor masses already selected for MS/MS acquisition were excluded for 
further selection during 30 s.  
 
3.7 Database Analysis and Configuration of Mascot Modifications  
MS data are analyzed as previously described (19). MS and MS/MS spectra are 
converted into Mascot generic format (mgf) using Proteome Discoverer, v2.1 (Thermo 
Fisher Scientific, Bremen, Germany). All high-resolution HCD MS/MS spectra are 
deconvoluted using MS Spectrum Processor, v0.9 (20). Searches were performed 
against the UniProtKB human database (taxonomy 9606, version 20140422), which 
includes 35’787 Swiss-Prot, 37’02 TrEMBL entries, 73’589 reversed sequences, and 
260 common contaminants. Mascot 2.5.1 (Matrix Science) is used for peptide 
identification using the following search settings: singly charged b and y ion series, 
immonium ions, and water and ammonia loss ion series are searched. Enzyme 
specificity is set to trypsin, allowing up to 4 missed cleavages. The ADP-ribose 
variable modification is set to a mass shift of 541.0611, with scoring of the neutral 
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losses equal to 347.0631 and 249.0862. The marker ions at m/z 428.0372, 348.0709, 
250.0940, 136.0623 are ignored for scoring. Lysine, arginine, glutamic- and aspartic 
acid are set as variable ADP-ribose acceptor sites. Peptides are considered correctly 
identified when a Mascot score >20 and an expectation value <0.05 are obtained. To 
assess the location of the ADP-ribose acceptor sites, we use the site localization 
analysis provided by Mascot, which is based on the work by Savitski et al. (20) and 
was developed especially for phosphorylation. Due to the lack of a better estimate, 
we define correctness as having a confidence of ≧95% in the Mascot site localization 
analysis (see note 8). 
 
Notes 
1. As an alternative to PARG treatment, enzymes converting ADP-ribose to 
phosphoribose (e.g. nudix hydrolases, snake venom phosphodiesterase I) can be 
used, but these require individually optimized reaction conditions and are expensive 
in the case of snake venom phosphodiesterase I (21,14). None of the available 
methods to date are capable of distinguishing between mono and poly-ADP-ribose 
acceptor sites. We envision that a specific set of binding proteins with affinities for 
either PAR or MAR, or conversion of PAR in to a specific moiety could solve this 
problem in the near future.  
2. We measured all our samples on an Orbitrap Fusion Tribrid mass spectrometer, 
but it is also possible to conduct a similar analysis on other mass spectrometers with 
optimized machine settings.  
3. Higher NAD+ concentrations can trigger the generation of very long ADP-ribose 
polymers that might interfere with trans-ADP-ribosylation or subsequent analysis.  
4. We started our analysis with 50 μg ARTD1 and ended up with enough material for 
9 mass spectrometry injections. The amount of initial starting protein and the peptide 
solution that is injected into the mass spectrometer need to be optimized depending 
on the efficiency of the ADP-ribosylation reaction, the HPLC and the mass 
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spectrometer used for the analysis.  
5. Partial drying of the peptides (leave 1-2 μl) increases the overall yield. 
6. To control for the enrichment and MS analysis, standard phosphopeptides can be 
added into the sample prior to sample preparation.  
7. Video tutorial describing how to build and use the stage tips (18): 
https://www.biochem.mpg.de/226863/Tutorials. 
8. This method is not optimized for ADP-ribosyl modifications due to the lack of 
standard peptides with known modification sites. For this reason, even if Mascot 
states a correctness of 95% for the site localization, this value is arbitrary and cannot 
be validated experimentally. 
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Figure 1 
HCD Fragmentation of an ADP-ribosylated peptide. (A) Representative annotated 
spectrum for the ARTD1 peptide VGHSIRHPDVEVDGFSELR that was found to be 
ADP-ribosylated on E76. ADP-ribose fragmentation ions are shown in red. (B) 
Nomenclature of ADP-ribose fragments as described by Hengel et al. (22). The ADP-
ribose fragment ions with strong signals in the HCD MS/MS spectra are shown.  
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3.2.4. Proteome-wide identification of endogenous ADP-ribose acceptor sites by 
Liquid Chromatography–Tandem Mass Spectrometry 
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Abstract  
ADP-ribosylation is a post-translational modification (PTM) affecting a variety of 
cellular processes. In recent years, mass spectrometry (MS)-based proteomics has 
become a valuable tool for studying ADP-ribosylation. However, it has remained a 
challenge to study this PTM in vivo in an unprejudiced and sensitive manner under 
physiological conditions. Here, we describe a detailed protocol for unbiased analysis 
of endogenous ADP-ribosylated proteins and their ADP-ribose acceptor sites under 
physiological conditions. The method relies on the enrichment of mono-ADP-
ribosylated peptides using the macrodomain Af1521, combined with high resolution 
liquid chromatography-tandem MS (LC-MS/MS). The 5-day protocol explains the 
enrichment of ADP-ribosylated peptides step-by-step from cell culture and all the way 
to data processing using the MaxQuant software suite [1].  
Key words: ADP-ribosylation, ADP-ribosylome, mass spectrometry, proteomics, 
Af1521 macrodomain enrichment, affinity purification, PARG 
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1. Introduction  
Protein ADP-ribosylation is a post-translational modification (PTM) where an ADP-
ribose moiety is transferred from NAD+ to the amino acid side-chains of target 
proteins (i.e. mono-ADP-ribosylation, MARylation). This protein bound ADP-ribose 
can subsequently serve as attachment points for the linkage of additional ADP-ribose 
units to form poly-ADP-ribosylation (PARylation). These chemical reactions are 
primarily catalyzed by ADP-ribosyltransferases (ARTs) and certain Sirtuin 
deacetylases [2,3]. A detailed understanding of the molecular mechanisms and 
functions affected by ADP-ribosylation remains elusive, since the amino acid residues 
modified by ADP-ribosylation in vivo remains unclear. Current experimental evidence 
suggests that ADP-ribosylation in eukaryotes primarily occurs on four different amino 
acids; Lys [4], Arg [5], Asp and Glu residues [6]. In addition, Cys residues were 
reported to be MARylated by certain ARTDs or bacterial toxins [7,8].  
 Protein ADP-ribosylation is a low abundant PTM that is rapidly degraded. To 
overcome this challenge cellular poly(ADP-ribosyl) glycohydrolase (PARG) levels are 
often knocked down by siRNA or its expression completely abolished by genetic 
deletion (i.e. using PARG knockout cells) [9,6]. Unfortunately, cellular absence of 
PARG affects the PAR homeostasis leading to physiological alterations in cells and 
mice [10-12]. Consequently, strategies requiring knockdown or omission of PARG 
constitute an unphysiological setting for analyzing cellular ADP-ribosylation and its 
associated mechanisms [13]. 
 High-resolution mass spectrometry (MS) has become a valuable tool for 
comprehensive identification of PTMs [14]. The two most current published MS-based 
approaches for mapping ADP-ribose acceptor sites in vivo are either biased towards 
modifications of only Glu and Asp [6], or lack sensitivity due to co-enrichment of 
several other PTMs (i.e. phosphorylated peptides) [9]. Moreover, a chemical genetic 
discovery method for ARTD targets was recently reported [15]. However, this 
approach renders the identification of ARTD-specific substrates under different 
cellular conditions, and at physiological NAD+ levels unattainable. Hence, to address 
these limitations we have developed a protocol for the unbiased mapping of 
endogenous ADP-ribose acceptor sites in proteins under genetically unperturbed 
physiological conditions [16]. Collectively, the protocol described herein represents a 
non-incremental advance in the detection of ADP-ribose acceptor sites and the 
identification of cellular processes regulated by ADP-ribosylation.  
 Together, the application of the described protocol allows the detection of the 
cellular ADP-ribosylome under defined conditions and will promote our understanding 
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of ADP-ribosylation as a regulatory mechanism of complex physiological and 
pathological processes.  
2. Materials and equipment  
All buffers are made using sequencing grade chemicals and Milli-Q water. 
 
2.1. Cell culture and lysis  
1. Cells of interest.  
2. Dulbeccos Modified Eagle Medium (D-MEM) supplemented with 10% fetal 
bovine serum (FBS) and penicillin/streptomycin (100 U/mL).  
3. Phosphate Buffered Saline (PBS).  
4. Hydrogen peroxide or alternative ADP-ribosylation-inducing agents of interest. 
5. Modified RIPA buffer (high salt): 50 mM Tris-HCl, pH 7.5, 400 mM NaCl, 1 mM 
EDTA, 1% NP-40, 0.1% Na-deoxycholate, 40 μM PJ-34, 1 μM ADP-HPD (Note 
1), Protease inhibitor cocktail. 
6. Modified RIPA buffer (no salt): 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1% NP-
40, Protease inhibitor cocktail.  
7. Acetone. 
8. Equipment: Cell lifters.  
9. Equipment: Centrifuge (with cooling) including a swinging bucket rotor. 
 
2.2. In-solution digestion  
1. Denaturation buffer: 6 M urea, 2 M thiourea, 10 mM HEPES, pH 8.0.  
2. Bradford reagent or alternative assay for measuring protein concentration.  
3. Reduction buffer: 1 M Dithiothreitol (DTT).  
4. Alkylation buffer: 550 mM Chloracetamide (CAA). 
5. Lys-C protease.  
6. Digestion buffer: 25 mM Ammonium Bicarbonate (ABC).  
7. Sequencing grade modified trypsin.  
8. 10% trifluoroacetic acid (TFA)  
9. Equipment: Centrifuge (with cooling) including a swinging bucket rotor. 
10. Equipment: Thermomixer.  
 
2.3 Concentration of peptides on Sep-Pak  
1. 100% acetonitrile.  
2. 0.1% TFA. 
3. Equipment: Centrifuge including a swinging bucket rotor.  
118 
 
4. Equipment: Sep-Paks.  
 
2.4 GST-protein expression and purification of Af1521 
1. Bacterial expression plasmid for N-terminal GST fused macrodomain Af1521 
[17]. 
2. BL21 competent E. coli cells.  
3. Super Optimal broth with Catabolite repression (SOC).  
4. Agar plates containing ampicillin (Amp-plates).  
5. Luria-Bertani (LB) medium.  
6. Terrific Broth (TB) medium.  
7. Isopropyl-beta-D-thiogalactopyranoside (IPTG) 
8. Lysis buffer: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM MgCl2, 1 mM DTT, 
1 x Bug Buster, 1 μL/mL Benzonase, 200 μg/mL Lysozyme, Protease inhibitor 
cocktail.  
9. Glass beads.  
10. Glutathione Sepharose 4B. 
11. Wash buffer: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM DTT.  
12. Equipment: Centrifuge (with cooling) including a fixed angle rotor for 
eppendorf tubes. 
13. Equipment: Centrifuge (with cooling) including a swinging bucket rotor 
 
2.5 Enrichment of ADP-ribosylated peptides 
1. 50% acetonitrile.  
2. 80% acetonitrile.  
3. 5 x Affinity precipitation (AP) buffer: 250 mM Tris-HCl, pH 8.0, 50 mM MgCl2, 
1.25 mM DTT, 250 mM NaCl. (For 1 x AP buffer dilute 5 x AP buffer in Milli-Q).  
4. hPARG is expressed and purified from insect cells as carboxyl-terminal His-
tagged protein and stored in liquid nitrogen.  
5. Purified Af1521. 
6. 0.15% TFA.  
7. Equipment: Vacuum concentrator (SpeedVac).  
8. Equipment: NanoDrop or alternative assay for measurement of peptide 
concentration. 
9. Equipment: Centrifuge (with cooling) including a fixed angle rotor for 
eppendorf tubes.  
10. Tabletop centrifuge. 
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2.6 Purification and desalting of peptides for mass spectrometric analysis  
1. C18 material.  
2. Methanol.  
3. Buffer B: 80% acetonitrile, 0.5% acetic acid. 
4. Buffer A: 0.5% acetic acid. 
5. Equipment: StageTip adapters for microcentrifuge tubes.  
6. Equipment: Centrifuge including a fixed angle rotor for eppendorf tubes. 
 
2.7 LC-MS/MS analysis of ADP-ribosylated peptides 
1. StageTip elution buffer 1: 40% acetonitrile, 0.5% acetic acid.  
2. StageTip elution buffer 2: 60% acetonitrile, 0.5% acetic acid.  
3. Buffer A*: 5% acetonitrile, 0.1% TFA.  
4. C18-packed nanospray column. We use 15 cm analytical columns (75 μm 
inner diameter) pulled and packed in-house with 1.9 μm C18 beads (Reprosil 
Pur-AQ, Dr. Maisch, Germany). 
5. Equipment: Liquid chromatography (LC) system e.g. nanoscale UHPLC 
system EASY-nLC1200.  
6. Equipment: Nanospray column heater (Sonation GmbH).  
7. Equipment: Mass spectrometer e.g. a Q Exactive HF.  
8. Data analysis software such as the freely available MaxQuant software suite 
(www.maxquant.org). 
 
3. Methods  
Here, we describe a sensitive and unbiased method for the identification of in vivo 
ADP-ribosylated sites using high resolution LC-MS/MS. The described protocol allows 
the study of basal ADP-ribosylation levels as well as their changes upon specific 
stimulations. In principle the protocol is applicable to any cell line of interest as long 
as enough material can be collected. The basal in vivo ADP-ribosylation activity has 
been described as low, but it is greatly increased by genotoxic stress in particular 
through the activation of ARTD1, and regulated by the opposing actions of PARG 
[18]. Thus, DNA shearing during cell lysis was shown to cause unphysiological PAR 
formation despite fast and gentle sample handling [19]. It is therefore crucial to 
complement the lysis buffer with PARP and PARG inhibitors in order to preserve the 
physiological ADP-ribosylome and avoid lysis-induced artifacts. In order to enhance 
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identification of ADP-ribosylation sites, the isolated proteins are digested to peptides 
and treated with PARG converting all PARylated amino acids to their MARylated 
counterparts. Although the PARG treatment prevents discriminating whether the 
modification was originally PARylation or MARylation, the conversion is crucial for 
feasible MS analysis. MARylated peptides can be unbiasedly enriched using ADP-
ribose-specific binders such as the Af1521 macrodomain, which has an affinity to 
ADP-ribose in the range of Kd ~ 0.13 μM [20,17,19]. Subsequently the modified 
peptides and their ADP-ribose acceptor sites are identified by high resolution LC-
MS/MS. 
The presented method can be divided into seven parts: cell culture and lysis, protein 
digestion, concentration of peptides, expression and purification of the Af1521 
macrodomain, enrichment of ADP-ribosylated peptides, purification of samples for MS 
analysis and analysis of the peptide mixture using LC-MS/MS.  
While the below described instructions are optimized for identification of ADP-ribose 
acceptor sites on in vivo modified proteins from cell cultures, the method is also 
suitable for the identification of the ADP-ribosylome from tissues. However, starting 
with tissues requires an optimization of different steps in particular the extraction 
conditions and will be discussed elsewhere.  
 
3.1 Cell culture and lysis  
1. Seed cells into eight 150 mm cell culture dishes per condition and grow them 
to approximately 80% confluency. This will yield approximately 30-40 mg of total 
protein.  
2. Wash cells once with warm PBS. Add H2O2 (0.5-1 mM) in PBS and incubate 
for 5-10 min at 37oC. (Note 2)  
3. Wash the cells carefully and briefly with ice-cold PBS and make sure to 
remove all PBS.  
4. Place the washed 150 mm cell culture dishes on ice and add 0.2 mL ice-cold 
modified RIPA (high salt) per plate. Incubate on ice for 5 min, scrape the cells off 
into the buffer, tilt the plate and transfer the lysis buffer and cells to a 15 mL 
falcon tube placed on ice.  
5. Centrifuge for 20 min, 4oC at 5000 x G to clear the lysate. Transfer 
supernatant to a 50 mL falcon tube for acetone precipitation.  
6. Dilute sample in salt-free RIPA (final concentration of NaCl of 133 mM) in 
order to make pellet easier to dissolve in urea.  (Note 3) 
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7. Acetone precipitate the proteins overnight by adding five-fold volume of ice-
cold acetone to reach a concentration of 80% acetone. Samples can be stored in 
acetone for several weeks. 
 
3.2 In-solution digestion 
1. Centrifuge the acetone precipitated proteins for 5 min, 4oC at 1000 x G and 
carefully discard the acetone completely by suction.  
2. At room temperature, add denaturation buffer (urea) to the 50 mL falcon tubes 
to dissolve the protein pellets. The added volume depends on pellet size. An 
ideal protein concentration is approximately 5 mg/mL. (Note 4) 
3. Determine protein concentration e.g. by Bradford reagent.  
4. Reduce disulfide bridges and unwind proteins by adding 1/1000 volume of 
reduction buffer (DTT), mix well and incubate for 60 min at room temperature 
shaking.  
5. Alkylate the free –SH groups by adding 1/100 volume of alkylation buffer 
(CAA) and incubate for 60 min at room temperature in the dark shaking. 
6. Cleave the proteins to peptides by adding proteases. Add 1 μg Lys-C for every 
100 μg protein to pre-digest the proteins. Lys-C will cleave at the carboxyl site of 
lysine residues. Incubate at room temperature for 3-4 hrs shaking. 
7. Dilute the sample 1:4 with 25 mM ABC to reduce urea concentration to <2 M. 
Make sure pH is 8.0-8.5, if pH is too high add water. 
8. Add 1 μg Trypsin for every 100 μg protein. Trypsin will cleave on the carboxyl 
site of lysine and arginine residues. Digest overnight at room temperature 
shaking. 
9. Carefully add 10% TFA dropwise until peptide solution has reached pH 2 in 
order to terminate trypsin digestion. The digested proteins can be stored at 4oC 
until further processing.  
 
3.3 Concentration of peptides on Sep-Pak  
1. Clarify the peptide mixture by centrifugation for 5 min, room temperature at 
1800 x G. Retain supernatant.  
2. Insert the Sep-Pak C18 column into a 10 mL syringe (use gravity flow and 
clamps). The capacity of the Sep-Pak is approximately 5% wt/wt of packing 
material weight.  
3. Add 5 mL of 100% acetonitrile to pre-wet the Sep-Pak cartridge.  
4. Wash the column by adding 2 x 4 mL 0.1% TFA. Remove bubbles in the top of 
the Sep-Pak by using a P-200 pipette to ensure flow through the material.  
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5. Load approximately 5 mL of the peptide mixture unto the Sep-Pak column at a 
time (the column might turn yellow) and remove any bubbles forming at the top of 
the Sep-Pak. Load the rest of the peptides.  
6. Wash the column by adding 3 x 5 mL Milli-Q water. Measure the pH of the 
flow-through. It must be >6, otherwise add more Milli-Q water. Store the Sep-Pak 
at 4oC until further use. The Sep-Pak can be stored at 4oC for several months.  
 
3.4 GST-protein expression and purification of Af1521  
1. Add 1 μL of cooled Af1521 plasmid to freshly thawn BL21, stir carefully and 
leave on ice for 15 min.  
2. Heat shock for 45 sec at 42oC.  
3. Incubate for 1 min on ice.  
4. Add 900 μL SOC and shake vigorously for 40 min at 37oC.  
5. Centrifuge for 2 min, room temperature at 2000 x G and discard approximately 
600 μL of the supernatant.   
6. Resuspend the bacteria in the remaining media, streak everything on to Amp-
plates and grow them overnight at 37oC.  
7. Inoculate a single colony in 5 mL of LB media containing ampicillin (1:1000) 
and grow them overnight at 37oC. 
8. Dilute the starter culture 1:500 in 200 mL pre-warmed TB media containing 
ampicillin (1:1000) in a 0.5 mL flask. (Note 5)  
9. Grow them at 37oC and measure OD600 continuously.  
10. Induce protein expression by adding freshly thawn IPTG (0.5 mM) when the 
OD600 is approximately 0.55-0.65.  
11. Express proteins for 5-6 hrs at 30oC.  
12. Pour 50 mL of the bacteria suspension into a 50 mL falcon tube and 
centrifuge for 15 min, room temperature at 3000 x G.  
13. Discard the supernatant and pour 50 mL of the bacteria suspension into the 
same 50 mL falcon tube.  
14. Centrifuge for 15 min, room temperature at 3000 x G, remove supernatant 
and freeze pellets at -80oC. Pellets can be stored at -80oC for several months.  
15. Thaw bacterial pellet and resuspend it in 4 mL freshly prepared lysis buffer. 
Incubate for 20 min at room temperature rotating.  
16. Break cells by adding glass beads and vortex for approximately 30 sec.  
17. Transfer liquid to microcentrifuge tubes and pellet cell debris by 
centrifugation for 5 min, 4oC at 14,500 x G.  
18. Transfer 2 mL of Glutathione Sepharose 4B slurry to a 15 mL falcon tube.  
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19. Add 8 mL of wash buffer and centrifuge for 2 min, 4oC at 2000 x G.  
20. Discard supernatant, add 9 mL of wash buffer and centrifuge for 2 min, 4oC 
at 2000 x G. 
21. Discard supernatant, transfer the cleared lysate to the 15 mL falcon tube 
containing the equilibrated beads and incubate for 4 hrs at 4oC head-over-tail 
rotating.   
22. Centrifuge the slurry for 2 min, 4oC at 2000 x G and remove supernatant. 
23. Wash the beads four times with freshly prepared wash buffer. Mix by 
inverting the tube 5 times. Centrifuge for 2 min, 4oC at 2000 x G.  
24. Remove the supernatant and resuspend the beads in wash buffer for a total 
volume of 10 mL. Proteins can be stored at 4oC coupled to beads for a few 
weeks. (Note 6)  
 
3.5 Enrichment of ADP-ribosylated peptides 
1. Elute the peptides off the Sep-Pak with 3 mL 50% acetonitrile followed by 1.5 
mL 80% acetonitrile.  
2. Aliquot the 4.5 mL elution-mix into four 1.5 mL microcentrifuge tubes. Add 40 
μL of 5 x AP buffer per tube, mix by pipetting up and down.  
3. Reduce the volumes to 200 μL per tube by vacuum centrifugation at 45oC. 
This will take approximately 60 min.  
4. Combine volumes of the four vials into one to attain a final volume of 800 μL.  
5. Clear peptide solution by centrifugation for 5 min, 4oC at 1800 x G. Cool on 
ice.  
6. Determine peptide concentration, e.g., at 280 nm using a NanoDrop. Use 
approximately 10 mg of peptides for enrichment of ADP-ribosylated peptides and 
save some for proteome analysis.  
7. Add 4.2 μg PARG enzyme per sample to reduce PAR complexity. Incubate for 
3 hrs at 37oC shaking.  
8. Cool down peptide mixture on ice.  
9. Add 500 μL of purified Af1521 macrodomain and incubate for 2 hrs at 4oC 
head-over-tail rotating.  
10. Centrifuge the peptides and slurry for 1 min, 4oC at 1000 x G and remove 
supernatant.  
11. Wash the beads three times with 1 mL of ice-cold 1 x AP buffer. Mix by 
inverting tubes 5 times. Avoid longer incubation. Centrifuge for 1 min, 4oC at 
1000 x G and remove supernatant.  
124 
 
12. Wash the beads three times with 1 mL of ice-cold Milli-Q water. Mix by 
inverting tubes 5 times. Avoid longer incubation. Centrifuge for 1 min, 4oC at 
1000 x G and remove supernatant.  
13. Elute the ADP-ribosylated peptides by addition of 100 μL 0.15% TFA to the 
beads, tap the bottom of the tube several times (do not vortex) and let stand at 
room temperature for 10 min.  
14. Tap the bottom of the tube again, centrifuge in a tabletop centrifuge for a few 
seconds, remove the supernatant using a gel-loading tip and transfer it to a new 
labeled microcentrifuge tube.  
15. Repeat elution step with additional 100 μL of 0.15% TFA for 10 min, combine 
the eluates and load onto C18 stage tips.  
 
3.6 Purification and desalting of peptides for mass spectrometric analysis 
1. Prepare one C18 StageTip for each sample. Making of StageTips are 
described in Rappsilber et al. [21]. We recommend stacking two C18 discs on top 
of each other for each StageTip.  
2. Activate the discs by adding 100 μL 100% methanol to the StageTips and let it 
pass through the C18 material by centrifuging for approximately 2 min, room 
temperature at 600 x G. It is important never to let the material run dry.  
3. Condition the discs by adding 100 μL Buffer B and centrifuge for 
approximately 2 min, room temperature at 600 x G.  
4. Equilibrate the discs by adding 100 μL Buffer A and centrifuge for 
approximately 2 min, room temperature at 600 x G.  
5. Load the eluted peptides onto the activated StageTip and centrifuge for 
approximately 4 min, room temperature at 600 x G.  
6. Wash the StageTips by adding 50 μL Buffer A and centrifuge for 
approximately 3 min, room temperature at 600 x G. Centrifuge until dryness. The 
StageTips can be stored at 4oC for several months.  
 
3.7 LC-MS/MS analysis of ADP-ribosylated peptides 
1. Elute StageTips by addition of 20 μL of StageTip elution buffer 1 followed by 
20 μL of StageTip elution buffer 2 into a 96 well plate suitable for the LC 
autosampler.  
2. Remove acetonitrile from the elutions by vacuum centrifugation until volume is 
approximately 7 μL. This will take approximately 25 min at 30oC. If less than 7 μL 
is left, fill up to 7 μL with Buffer A. 
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3. Add 1 μL of Buffer A* to all wells.  
4. Design a LC gradient of 60 min or more. We recommend analyzing each 
sample using a 180 min gradient ranging from 5% to 64% acetonitrile in 0.5% 
formic acid at a flow rate of 250 nL/min. (Note 7) 
5. Injection volume should be kept to 5 μL or below for each sample. (Note 8) 
6. For separation of peptides we typically use an in-house packed analytical LC 
column made from a 20 cm long fused silica with 75 μm inner diameter and 
packed with 1.9 μm C 18 beads.  
7. To facilitate identification of ADP-ribosylated peptides it is recommended to 
operate the Q-Exactive mass spectrometer using the previously described 
‘sensitive settings’ [22] (Note 8). Briefly, the sensitive settings correspond to a top 
10 method on the Q-Exactive with 60,000 MS resolution and 60,000 MS/MS 
resolution 
8. The scan range for the MS should be set to 400–1600 m/z, for MS/MS fixed 
first mass should be set to 100 m/z.  
9. Automatic gain control AGC target for MS should be set to 1e6 or higher, for 
MS/MS it should be 10× lower (100,000 in this case). 
10. Keep maximum injection at 45 ms for MS and 110 ms for MS/MS. 
11. Normalized collisional energy should be set to a value between 25 and 30, we 
recommend 28 as safe median. 
12. Dynamic exclusion should be set to 30 s. 
13. Process raw files using the MaxQuant software suite supported by the 
Andromeda search engine. We use the following settings:  
Fixed modifications: Carbamidomethyl (C)  
Variable modifications: Oxidation (M), Acetyl (Protein N-term), mono-ADP-
ribosylation (C10H13N5O9P2) on lysine, arginine, glutamic acid and aspartic acid. 
To increase confidence in identified ADP-ribosylated peptide identifications, we 
typically add neutral losses and diagnostic ion masses in the MaxQuant search 
parameters (Note 9). 
Max. missed cleavages: 3  
Min. peptide length: 7  
Protein FDR: 0.01; Peptide FDR: 0.01; Site FDR: 0.01. 
 
4. Notes  
1. The stability of ADP-HPD in solution is critical. Following reconstitution of the 
powder, aliquots are only stable for up to 1 week at -20°C.  
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2. We do recommend treating the cells in some way to induce ADP-ribosylation. 
In our hands, treatment with H2O2 for 5-10 min increases the number of ADP-
ribosylated targets significantly. Several other DNA damage-inducing agents can 
be used.  
3. Protein concentration can be determined after lysis (e.g. by Bradford) and an 
aliquot of the protein lysate can be kept for western blotting. If stable isotope 
labeling by amino acids in cell culture (SILAC) is applied, we recommend mixing of 
SILAC samples before acetone precipitation. Alternatively, samples can be mixed 
when dissolved in urea.  
4. It is important to add urea to the protein pellets at room temperature. At low 
temperatures, urea will crystalize while it will induce artifacts at higher 
temperatures [23].  
5. If possible, we recommend making several starting cultures for preparation of 
a large batch of Af1521.  
6. For western blot analysis, we recommend crosslinking the macrodomain to the 
sepharose beads. In brief, wash resin three times with 10 mL 0.2 M borate-NaOH, 
pH 9.0. Centrifuge for 2 min, room temperature at 2000 x G. Add 10 mL freshly 
prepared DMP solution (20 mM) and incubate for 60 min, room temperature head-
over-tail rotating. Centrifuge for 2 min, room temperature at 2000 x G. Stop 
crosslinking reaction by adding 10 mL 0.1 M glycine-HCl, pH 2.5 to remove non-
covalently linked molecules that may be present due to reduced coupling 
efficiencies. Crosslinking can be verified by SDS-PAGE. GST-protein should only 
elute from the resin prior to addition of DMP.  
7. Described LC settings are applied for the analysis of enriched ADP-ribosylome 
from treated cells. The gradient have to be adapted based on the complexity of the 
sample and used instrumentation.  
8. An injection volume of 5 μL will take approximately 20 min to load onto the 
column at a constant pressure of 500 bars. An injection volume of more than 5 μL 
will result in longer loading times. By using a nanoscale UHPLC system e.g. 
EASY-nLC1200 (Thermo Fisher Scientific) the loading pressure can be increased 
and the loading time thereby shortened.  
9. To help assign ADP-ribosylated peptides in MaxQuant, the following 
parameters can be added to the Andromeda search engine:  
Monoisotopic mass: 541.0611088074  
Composition: H(21)C(15)N(5)O(13)P(2)  
Position: notCterm  
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NeutralLoss: H(21)C(15)N(5)O(13)P(2) for lysine, arginine, aspartic acid and 
glutamic acid. 
Diagnostic peak: H(5)C(5)N(5), H(11)C(10)N(5)O(3), H(14)C(10)N(5)O(7)P, 
H(15)C(10)N(5)O(10)P(2), H(21)C(15)N(5)O(13)P(2) for lysine, arginine, aspartic 
acid and glutamic acid. 
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3.2. Unpublished results 
3.3.1. Identification of ADP-ribosylation sites on in vitro ARTD1, ARTD2 and ARTD10 
using m-aminophenylboronic enrichment 
The exact mechanism how ARTD enzymes catalyse ADP-ribosylation at all four 
known acceptor sites (lysine, arginine, glutamic, and aspartic acid) is not studied. To 
gain insight into the enzyme specificity, we evaluated auto-modification sites present 
on ARTD1, ARTD2, and ARTD10. To increase the amount of modified peptides for 
downstream MS/MS analysis, we performed m-aminophenylboronic beads enrichment 
following the protocol published by Zhang et al. [117]. Indeed, we were able to 
localize E and D modification sites on all three enzymes. Only two ADP-ribose 
acceptor sites were assigned on ARTD10, which can be associated with the low 
activity of the recombinant full-length protein. The application of this procedure to in 
vitro modified ARTD2 led to the identification of previously unknown acceptor sites. 
Previously published ARTD1 acceptor sites [152] were confirmed by this method 
(Figure 8). In conclusion, all four enzymes were able to perform auto-modification 
reaction targeting E and D acceptor sites.  
 
 
Figure 8. Identified acceptor sites of in vitro modified ARTD1 and ARTD2 using m-
aminophenylboronic beads.  The position and site of the identified ADP-ribosylation are marked 
with vertical labels. Red marks D sites, blue marks E sites. ZnI-III – Zn-finger domains, PRD – 
PARP regulatory domain, GRD - glycine-rich domain. * indicates new ADP-ribosylated acceptor 
sites. 
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3.3.2. Potential oxidative stress-induced ADP-ribosylome identified with the m-
aminophenylboronic beads enrichment  
Considering the successful application of m-aminophenylboronic beads to in vitro 
proteins, analysis of in vivo ADP-ribosylated samples was the next step to understand 
the function of ADP-ribosylation. Next, we evaluated the application of m-
aminophenylboronic enrichment method to complex samples like cell lysates. First, 
the ability of m-aminophenylboronic beads to pull down in vitro modified ARTD1 
spiked into HeLa lysate was tested. Indeed, ARTD1 was efficiently bound to the beads 
and enriched from this complex background. Unspecific binding of GAPDH was 
removed by four consequent washes (Figure 9A). Second, the efficiency of HA elution 
was evaluated with in vitro modified PARylated ARTD1. The binding of ARTD1 to 
the beads was strong, and HA elution released barely detectable amounts of modified 
protein from the beads (Figure 9B). Although the elution efficiency was low for 
ARTD1 bound to m-aminophenylboronic beads and eluted with HA, it was enough for 
MS/MS analysis (as shown in Figure 8).  
However, the efficient elution is critical for an analysis of a cell lysate as the HA 
elution of cell lysate pull-down was empty. To overcome the inefficient elution, we 
decided to perform on-beads digest of the bound proteins. To preserve the 
modification from degradation during the lysis procedure, MEFs PARG -/- cells were 
selected for the experiment. The cells were either treated with 1mM H2O2 or with PBS 
as a control. The lysates were then incubated with m-aminophenylboronic beads and 
bound proteins were digested with trypsin. Released proteins were analysed by 
Figure 9. Binding of ADP-ribosylated ARTD1 to m-aminophenylboronic beads. A). Recovery of 
in vitro ADP-ribosylated ARTD1 from a complex background.  in vitro ADP-ribosylated ARTD1 was 
spiked into 30 µg of HEK lysate. B). in vitro modified ARTD1 is eluted inefficiently from m-
aminophenylboronic beads. Input represent 100% of used material. b/b – bound beads, where b/b1 – 
beads before washes and b/b2 – beads after washes. Elution (marked as elu) was performed with 0,5 M 
HA overnight.  
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MS/MS to identify the proteins that bind to m-aminophenylboronic beads. Since the 
lysis was performed under denaturing conditions (1% SDS), all interactions between 
the proteins were disturbed. Thus, only potentially modified proteins are bound to the 
beads (Figure 10).  
The proteins identified in 1mM treated sample showed GO enrichment for DNA 
repair proteins and nuclear proteins. Moreover, the proteins were enriched for 
functional GO terms associated with DNA and RNA binding. Interestingly, ARTD2 
was identified as one of the hits. The proteins shared between the samples were not 
enriched for nuclear proteins, although some of the nuclear proteins like Histones and 
ARTD1 were present in this category.  
Moreover, some of the proteins in both groups e.g. Zink transporter ZIP6 and 
Sodium- and chloride-dependent taurine transporter localized to the membrane. Due to 
the chemical mechanism of m-aminophenylboronic enrichment, the beads enrich any 
ribose-containing substrate, e.g. membrane localized glycosylated proteins. Since the 
ADP-ribose acceptor site assignment was not possible with this method, validation of 
the potential candidates has to be carried out to confirm the presence of ADP-
ribosylation and identify the sites.  
3.3.3. Oxidative stress-induced ADP-ribosylome is significantly overlapping in HeLa 
and U2OS cells 
After the development of Af1521 pull down, the identification of ADP-ribosylated 
proteins and site assignment became feasible in single MS/MS measurement [153]. 
Af1521 enrichment method was applied to HeLa and U2OS cells, commonly used in 
genotoxic stress response studies, to understand cell type variability of ADP-
ribosylome in oxidative stress. For that, the cell lines were treated with 1mM of H2O2 
for 10 min to trigger PARylation. Both cell lines showed overlap for the identified 
ADP-ribosylome (Figure 11A), indicating that the oxidative stress-induced ADP-
Figure 10. Identified proteins 
pulled down with m-
aminophenylboronic beads. Venn 
diagram represents the overlay 
between 1mM and untreated 
samples (n=3). Some of the known 
ADP-ribosylation targets are 
indicated by an arrow in the unique 
1mM and common protein groups. 
134 
 
ribosylome is not cell type specific, but rather a constant set of oxidative stress-
responsive proteins.  However, we detected the fewer number of ADP-ribosylated 
proteins in U2OS cells. The low number of identifications points on faster catabolism 
of the modification or different dynamic of ADP-ribosylation in these cells.  
Since m-aminophenylboronic beads enrichment was performed in MEFs and 
showed promising results, we applied the Af1521 method to the same cells (Figure 
11B). PARG -/- showed the significantly larger number of identified proteins 
compared to wildtype cells. The increased number of ADP-ribosylated proteins in 
PARG -/- clearly points that PARG plays a key role in the dynamic of the 
modification in cells. Moreover, as was shown by Jungmichel et al. [121] PARG -/- 
leads to increased level of PARylation in cells. Whether the proteins gain the 
modification under physiological conditions remains to be confirmed.  
3.3.4. Increased ADP-ribosylome size in ARTD2 -/- and ARTD3 -/- U2OS cells 
To understand the target specificity of ARTDs in oxidative stress, we performed 
Af1521 pull-down on U2OS cells, which were CRISP-Cas9 recombined to remove 
ARTD1, ARTD2, and ARTD3 (kindly provided by K.W.Caldecott). First, to gain 
insight into qualitative changes of ADP-ribosylome, we analysed the enriched sample 
with shotgun MS/MS (Figure 12, Table 3).   
Only three modified proteins were identified in ARTD1 -/- sample independent 
of the treatment. Among these proteins, we detected most abundant nuclear proteins: 
H2B histone and HNRNPU and ER-localized protein PDIA3. In other cell lines, we 
Figure 11. Oxidative stress induced ADP-ribosylome of different cell lines identified with Af1521 
pull-down. The cells were treated with 1mM H2O2 A). Venn diagram showing the overlap between 
oxidative stress-induced ADP-ribosylome in HeLa and U2OS cells. B). Venn diagram showing the 
overlap in ADP-ribosylome of MEFs cells WT or PARG -/-. Upon knockout of PARG, the increased 
number of identification is observed. U2OS n=1, MEFs n=1, HeLa n=7 
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observed oxidative stress-
dependent induction of the ADP-
ribosylation level. Surprisingly, 
ARTD2 -/- and ARTD3 -/- cells 
had a larger number of assigned 
modified proteins when compared 
to WT. This qualitative increase 
of ADP-ribosylome indicates the 
possible regulation of ARTD1 
activity by either/both enzymes. 
Nevertheless, ARTD2 or ARTD3 
auto-modification was not 
observed.  
Protein name Peptide sequence Score 
Expectation 
value 
HNRNPU EAAG(K)SSGPTSLFAVTVAPPGAR 46.85 4.60E-05 
PDIA3 (R)LAPEYEAAATR 33 0.0082 
HIST1H2BJ P(E)PAKSAPAPK 27.51 0.033 
Table 3. Proteins ADP-ribosylated in ARTD1 -/- U2OS cells. ADP-ribosylation site is indicated in 
brackets.  
3.3.5. H2B ADP-ribosylation at the position 2 is neither a target of ARTD1, ARTD2 
nor ARTD3 in vitro  
Histone H2B ADP-ribosylation at position 2 (depending on the isoform either E or D 
site) is a highly abundant modification that is present also in basal conditions. Previous 
in vitro experiments showed that ARTD1 is not the writer of the site [154]. However, 
the study was performed with truncated short peptides fused to GST at N-terminal that 
potentially can interfere with the enzymatic reaction. To find the writer of the 
modification, we repeated the modification assay with all three DNA-dependent 
ARTDs i.e. ARTD1, ARTD2 and ARTD3 (Figure 13B) using H2B tail. ARTD1 and 
ARTD3 modified GST-H2B tail, while ARTD2 did not show any trans-modification. 
Further to elucidate the potential modification site we performed the reaction with 
GST-H2B mutants: E2 to A (m1), first 4Ks to 4A (m2), and 3Rs to A (m3) (Figure 
13A). The other K sites present on H2B tail since they were not identified  
Figure 12. Oxidative stress induced ADP-ribosylome of 
U2OS ARTDs KO cells. Venn diagram shows the overlap 
in the identified modified proteins identified after 1mM 
H2O2 treatment in U2OS cells WT, ARTD1-/-, ARTD2-/- 
and ARTD3 -/-. Three proteins identified in ARTD1 -/- are 
indicated in Table 3. 
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as acceptor sites of modification by a previous study [154]. Surprisingly for us, neither 
of the enzymes showed the specificity towards E2 site, since E2 to A mutant was still 
modified to the same extent as WT protein. The assay indicated that both enzymes 
potentially modify Ks and Rs present on the tail as for both K and R mutants the 
modification level dropped almost 100%. However, 3-4 point mutations introduced 
into the H2B tail changed the electrical charge of the protein that might interfere with 
the biochemical reaction. In this case, the tail was not recognized by ARTDs as 
potential substrate. Moreover, H2B tail used in this experiment has N-terminal GST 
tag that potentially can cover the modification site from the enzyme.  
3.3.6. H2B ADP-ribosylation at the position 2 is neither a target of ARTD1 nor ARTD3 
in vivo 
To obtain information about quantitative changes in ADP-ribosylation upon ARTDs 
KO, we performed PRM measurement with ARTD1-/- and ARTD3-/- cells. WT cells 
were used as a control. In consistency with shotgun measurement (see section 3.3.4), 
only a few sites were modified in ARTD1 -/- cells. Moreover, no ADP-ribosylation 
induction was observed upon 1mM H2O2 treatment (Figure 14). This result indicates 
that ARTD1 mainly catalyse an oxidative stress-induced ADP-ribosylome. 
Interestingly, ADP-ribosylation of PDIA3 and P4HB (also known as PDIA1) was 
downregulated in ARTD3 -/- cells in untreated as well as in H2O2 treated sample. 
Considering the different localization of ARTD3 and downregulated proteins, the 
Figure 13. in vitro modification of H2B tail. A). Sequences of H2B tails used in the in vitro reactions. 
The mutated sites are underscored on WT sequence and shown in red on the mutant tails (named as m1-
3) B).Trans-modification of H2B tail with ARTD1, ARTD2, and ARTD3. C). Trans-modification of 
H2B tail carrying mutations at potential modification sites with ARTD1 and ARTD3. Oxidative stress-
induced H2B ADP-ribosylation at the position 2 is not a target of ARTD1 or ARTD3 in vivo  
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signaling pathway connecting ER and nucleus is potentially involved in this 
downregulation.   
One of the few proteins that was still modified in ARTD1 -/- cells was histone 
H2B. Three isoforms (with a difference at the position 4) of H2B histone were 
detected in the samples. Although the measurement was performed only once, several 
preliminary conclusions can be made. First, ADP-ribosylation levels changed 
differently in different histone isoforms. For example, H2B isoform K did not show 
induction upon H2O2 treatment in WT cells (induction 1.8 fold), whereas other 
isoforms were upregulated around 15 fold. Second, ARTD3 does not contribute to the 
modification level of H2B tail at the monitored site for D and K isoforms. However, 
ARTD3 potentially can modify B isoform since the basal modification level was 
downregulated in ARTD3 -/- cells. Third, ARTD1 is not the only enzyme that writes 
the modification. The level of H2B E2 modification was decreased in ARTD1 -/- cells 
but was clearly detectable (except isoform B). ARTD1 -/- H2B modification level 
increased upon oxidative stress indicating that other ARTD carried out the reaction in 
these cells.  
Figure 14. Quantification of ADP-ribosylation in U2OS ARTDs KO cells. A). Heatmap represents 
the quantitative differences between the samples. The total fragment intensity for each peptide was log2 
transformed. The blue intensity correlates with the abundance of the ADP-ribosylated peptide. B). 
Quantitative differences in H2B E2 ADP-ribosylation is shown. The amino acid that is different for 
each isoform is underscored. ADP-ribosylation site is labelled in red. 
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3.3.7. Methods for unpublished results 
m-aminophenylboronic beads enrichment. The protocol was adapted from [117]. 
For in vitro reaction, elution was performed with 0.5 M NH2OH overnight at room 
temperature on an end-to-end rotator. Cell lysate enrichment performed on protein 
level with m-aminophenylboronic acid–agarose (Sigma). Loaded with protein beads 
were washed with 50 mM ammonium bicarbonate pH8. The beads were then 
incubated with 5 mM dithiothreitol for 1h at 37oC, followed by 5 mM chloroacetamide 
for 1h in the dark. The trypsin digest was performed overnight at 37oC with gentle 
shaking. 0.15% trifluoroacetic acid was added to the reaction to stop the digest, and 
the supernatant containing peptides was collected. GO analysis was performed with 
Panther database (http://pantherdb.org).  
In vitro modification assay with ARTDs. The reactions were performed as described 
in method paper with following modifications. 5 pmol DNA template was added to the 
reaction to activate the enzymes. 40 mer was used to activate ARTD1 and 40 mer with 
a nick (5’ phosphate) for ARTD3. For trans-modification reaction, 50 pmol target 
protein was added into the reaction. The reaction was carried out at 30oC for 15 min. 
For pull-down experiments, a total of 50 µg of modified enzyme was used. To 
generate this amount of modified protein, several reactions were performed in parallel 
and pulled together before the enrichment step.   
Enrichment of ADP-ribosylated peptides with Af1521. The enrichment is 
performed as described [153]. 
MS/MS analysis of U2OS ARTDs -/- cells. The ADP-ribosylated peptides were 
analysed on Orbitrap FUSION Tribrid with HCD(FT)-PP-HCD/EThcD method [155]. 
PRM method was adapted from [156] and new targets were included based on shotgun 
measurements. The data analysis was performed using Skyline-daily (v3.5.1.999). 
mProphet second best peak model was trained on WT sample and used to perform 
automatic peak peaking. FDR was set to 0.05. Unsupervised clustering heatmap was 
generated with R using “R for Proteomics” package.  
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4. DISCUSSION AND PROSPECTIVE  
4.1. Summary of the results 
Despite over 50 years of ADP-ribosylation research, in-depth knowledge about the 
cellular function of this modification is still missing. The difficulties are mainly 
associated with the lack of appropriate tools used to study this complex protein 
modification. Thus, this thesis was aimed at defining the oxidative stress-induced 
ADP-ribosylome in various normal and cancer cell lines and to analyze its changes at 
the quantitative and qualitative levels using mass spectrometry-based assays.  
The first objective was to identify the ADP-ribosylome specifically during 
oxidative stress. To enrich low abundant protein ADP-ribosylation from cell lysates, 
we established an enrichment method using the Af1521 macrodomain, which binds 
MAR and PAR with strong affinity. The developed enrichment step in combination 
with MS/MS analysis enabled the identification of ADP-ribosylated proteins and their 
acceptor sites both in stressed cells and in mouse organs [153]. To further improve the 
identification of ADP-ribosylated proteins and the assignment of the modified site (i.e. 
ADP-ribose acceptor site), we have developed an optimized shotgun HCD(FT)-PP-
HCD/EThcD method employing special features of ADP-ribose fragmentation. This 
method allows an in-depth characterization of the cellular ADP-ribosylome with high 
confidence of the acceptor site assignment. The obtained high-quality dataset enabled 
us to identify a K modification site motif [155].  
The second aim of the project was to understand the qualitative and quantitative 
changes of protein ADP-ribosylation under various degrees of oxidative stress. Using 
a shotgun quantification approach, we observed that for high levels of oxidative stress 
(64 µM-1 mM of H2O2), the ADP-ribosylome remains qualitatively and quantitatively 
stable. To detect changes under low oxidative stress (0-16 µM of H2O2), we improved 
the reproducibility of the quantification measurements by developing a parallel 
reaction monitoring (PRM) method targeting defined ADP-ribosylated peptides. 
Application of the PRM method enabled us to monitor changes in ADP-ribosylation. 
While the ADP-ribosylation levels increased for many tested proteins, surprisingly we 
also detected a decrease of ADP-ribosylation for some targeted proteins at a low 
degree of oxidative stress in HeLa cells [156]. Finally, we applied the developed PRM 
method to a set of ovarian cancer cell lines challenged with oxidative stress. The 
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obtained results indicate a lower abundance of ARTD1 and a tighter regulation of its 
activity in PARPi resistant cell line. 
4.2. Unbiased enrichment method for ADP-ribosylation 
A significant improvement of ADP-ribosylation enrichment methods has been 
achieved during the last five years. Several approaches were developed, and their 
combination with shotgun MS analysis identified the ADP-ribosylome under basal 
(i.e. untreated) and stress conditions [117, 121, 124].  We identified the ADP-
ribosylome of HeLa cells upon oxidative stress [153]. The overlap of identified ADP-
ribosylated proteins between the different studies is rather modest (not more than 
40%) [153, 157]. However, since the studies were performed using different 
enrichment methods and cell types, a careful interpretation of the published results is 
necessary to define a common cellular ADP-ribosylome. Gibson et al. identified ADP-
ribosylated targets using a chemical genetic discovery approach with NAD+ analogues 
and analogue-sensitive ARTD enzymes [124]. The overlap of ADP-ribosylated 
proteins identified in this study was 30% with our Af1521 enrichment results [153]. 
Considering the generally modest reproducibility of shotgun measurements [158], 
such an overlap can be considered as good. Moreover, Gibson et al. identified targets 
of ARTD1, 2 and 3, whereas the ADP-ribosylome upon oxidative stress identified by 
our Af1521 pull-down is mainly ARTD1 dependent (Figure 12). The enzymes 
analyzed in the Gibson et al. study were activated by sperm DNA, a strong inducer of 
DNA-dependent ARTD activity. Moreover, since the experiments were performed 
after cell lysis, the cellular localization of the proteins was disturbed. Two questions 
arise: (1) whether these proteins are indeed ADP-ribosylated under physiological 
conditions and (2) which stimulus triggers their modification. The results reported by 
Zhang et al., where oxidative stress was used as an inducer for ADP-ribosylation in 
vivo, are more comparable to our dataset. [117]. The overlap between the reported 
ADP-ribosylomes is 40%. However, several factors should be considered. First, the 
PARG-/- background used by Zhang et al. potentially causes perturbations in the 
regulation of ADP-ribosylation. Increased PAR formation in PARG-/- cells was 
detected by western blot [121] and by immunofluorescence [159] in oxidative stress-
induced as well as under basal (untreated) conditions. Second, the acceptor site bias 
introduced by HA elution from m-aminophenylboronic beads (allowing identification 
of E and D sites only) is a limiting factor for the identification of a comprehensive 
ADP-ribosylome.  
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To date, Af1521 is the most unbiased approach to characterize ADP-ribosylation 
under physiological conditions since it enables the identification of all four acceptor 
sites without the need to knockout PARG. Nevertheless, we cannot exclude the 
possibility of specific substrate recognition by the Af1521 domain. Since the domain 
has particular functions in cells, the domain might bind a preferential protein sequence 
and/or preferential acceptor sites. E.g. in oxidative stress-induced HeLa cells, K was 
identified as the dominant ADP-ribose acceptor [153]. This preference can be 
explained either by the specificity of ARTD1 to modify Ks upon oxidative stress or by 
the specificity of Af1521 to bind K-linked ADP-ribosylation. The fact that Rs in 
mouse organs were identified as major ADP-ribose acceptor sites [160] rather points 
to the first explanation. Nevertheless, the linkage specificity of Af1521 can still not be 
completely ruled out (i.e. specificity towards basic acceptor sites). Indeed, studies to 
biochemically characterize the properties of ADP-ribose binding domains are usually 
performed with free ADP-ribose or its derivatives [44]. Thus, it is not clear if the 
studied domains have substrate specificity, and if so, which factors would define it. 
Along this line, MacroD1 and TARG showed different affinities for ADP-ribosylated 
peptides in vitro [161]. If this specificity would also be confirmed in vivo, the quality 
of domains could be used to better characterize cellular ADP-ribosylation in various 
conditions by performing a combination of pull downs with different macrodomains. 
E.g., domains with a potential specificity for R sites would allow identifying ADP-
ribosylated proteins with these acceptor sites. Moreover, knowledge about the 
macrodomains in combination with bioinformatics analysis (GO analysis, motif 
search) and cell culture techniques (e.g. siRNA screening), might help to define the 
writer and potentially the eraser of certain modification sites as well as novel functions 
of ADP-ribosylation.  
4.3. Protein ADP-ribosylation as a marker of stressed cells  
Oxidative stress is a pathological cellular condition involved in the development of 
many diseases such as age-related metabolic diseases, acute neurological disorders, as 
well as chronic neurodegenerative diseases and cancer [162, 163]. Here, we show that 
oxidative stress-induced ADP-ribosylation is mainly mediated by ARTD1. Indeed, the 
involvement of ARTD1 activity has been reported for many of these oxidative stress-
induced diseases [163, 164]. Moreover, most proposed theories of PARPi action are 
based on the inhibition of the enzymatic activity of ARTD1 [165], although many 
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PARPi are not specific [88]. Thus, the activity of ARTD1 could potentially be used to 
predict the efficacy of PARPi treatment and/or to define the stage of a certain disease. 
Therefore, a more detailed understanding of protein ADP-ribosylation dynamics in 
response to oxidative stress may be a useful tool to detect pathological conditions. 
The National Institute of Health (USA) defines a biomarker as “a characteristic 
that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” [166]. Due to their core function in cellular events and their relatively 
easy accessibility through body fluids, proteins are the best candidates for use as 
biomarkers compared to other cellular components. MS-based proteomics is a 
powerful tool that boosted the search and validation of biomarkers for cancers and 
other pathological conditions. At an early stage, shotgun discovery methods are used 
to identify potential biomarkers, which are further validated by targeted MS proteomic 
analysis [167]. The profiling of cancer cells using SRM allowed measurements of over 
1000 cancer-associated proteins [168]. Thus, the ADP-ribosylation field has all the 
necessary tools to test and validate ADP-ribosylated proteins for their predictive 
properties. Here, we showed that cancer cells have a variability regarding ARTD1 
abundance. Additionally, the basal and H2O2-induced ADP-ribosylomes also vary 
[156]. However, this is just a first step to understand if these differences could be used 
as predictive biomarkers.  
In our studies, we concentrated our efforts on the oxidative stress-induced ADP-
ribosylome. Interestingly, ovarian cancer cells had different basal and H2O2-induced 
ADP-ribosylomes. This observation raises the question if there are other pathways 
able to induce ADP-ribosylation in cancer cells. These pathways might drive PARPi 
sensitivity. Indeed, PARPi might function via disturbance of cellular energy 
metabolism [107]. Thus, to understand PARPi sensitivity, quantitative ADP-
ribosylation studies should be performed under different stimuli.  
It would be interesting to test if oxidative stress-induced ADP-ribosylated targets 
are also detected in blood samples. Blood is a convenient patient sample since its 
collection is a standard routine procedure in clinics. Although MS measurements of 
blood plasma are well established, they remain a challenging task. Half the blood 
protein content consists of albumin, the most abundant protein in plasma [169]. 
However, the level of albumin is constant and has not been reported to change under 
any conditions, [170]. Thus, established MS protocols suggest depleting albumin to 
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uncover interesting candidates that otherwise would be shielded by highly abundant 
proteins. Optimization of enrichment protocols will be necessary to evaluate the 
amount of required material and adaptation for blood samples. Since ARTC enzymes 
are localized on cellular membranes, their interference with detection of ARTD ADP-
ribosylated targets should be considered. 
4.4. Perspective of MS-based quantification of ADP-ribosylation 
Quantitative MS measurements are a valuable tool to study the dynamics and 
functions of PTMs in cells. Here, we developed a PRM method to study ADP-
ribosylation in stressed cells [156]. PRM measurements are ideal comparing different 
experimental conditions in a reproducible manner. They help to quantify the 
modification level of cells as well as studying the function of ADP-ribosylation writers 
and erasers in detail. Upon knockout of a respective ARTD enzyme, changes at the 
level of specific ADP-ribosylation sites can be monitored using a PRM method. Here, 
we applied the PRM method to study ARTD specificity by monitoring the E2 ADP-
ribosylation site identified on various H2B isoforms under basal and oxidative stress-
induced conditions. Our in vitro modification assays revealed that ARTD1 and 
ARTD3 can modify the H2B tail (Figure 13B). Performing PRM measurements of 
U2OS cells indicate that mainly ARTD1, not ARTD3, is the writer of the H2B E2 
modification site (Figure 13). One possible explanation for this contradiction is that 
ARTD3 is modifying the H2B tail at a different position. Indeed, in vitro modification 
assays using an H2B mutant (E2A) revealed that ARTD3 does not target the E2 site, 
but rather a different site (Figure 13C).  
PRM measurements can be used to analyze quantitative differences of specific 
acceptor sites present on the same peptide. In several cases, ADP-ribosylated peptides 
were eluting from the LC either in double-fused peaks or in two separate peaks. 
Usually, these peaks shared several common fragment ions [156]. Their shift of 
retention time indicates that they have various physical qualities, which potentially 
could be generated from differentially modified acceptor sites on the same peptide. 
Unfortunately, in many cases, the precise localization of the modification is difficult to 
define. By extracting characteristic fragment ions (i.e. just before and after the 
acceptor site), it would be possible to localize the modification. Furthermore, by 
knowing the quantitative differences of various acceptor sites, it would be possible to 
better understand the function of these specific sites. ARTD1 is known for its 
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extensive auto-ADP-ribosylation, especially when the protein is analyzed in vitro. 
However, it is not clear whether all identified sites play a functional role. By targeting 
all ARTD1 sites with PRM, it would be possible to correlate acceptor sites with 
specific stimuli, which trigger their modification.  
One of the main problems of the ADP-ribosylation PRM measurements was the 
absence of suitable standards. At the moment, only one standard peptide is available 
[171]. Although it is a valuable tool to monitor the variability between analyzed 
samples after enrichment, it does not allow to perform proper normalization. Only fold 
changes greater than 2 can be reliably measured, leading to high variability. This is not 
a problem for the H2O2-induced ADP-ribosylome since the observed induced ADP-
ribosylation levels are high (reaching up to 40-fold induction over basal levels) [156]. 
However, for other conditions, the changes might potentially be smaller. Thus, it 
would be critical to introduce additional standards. Nowadays, the chemical synthesis 
of ADP-ribosylated peptides is difficult. The way to bypass this might be to use 
protein glycation [19], which allows obtaining peptides with modified Ks. Moreover, 
many peptides contain more than one possible acceptor site. The PRM method targets 
and measures specific m/z of the precursor and the position of ADP-ribosylation is 
irrelevant for the method development. It would thus be possible to create peptides 
analogous to cellular peptides with E, D, and R sites if they have K in their sequence 
(which would be glycated). Unfortunately, for peptides with multiple K sites, this 
strategy does not work. The potential disadvantage of targeted proteomics methods 
lies in their data dependency. It is critical to know the fragmentation of a targeted 
peptide in advance. The information about fragmentation and LC behavior of the 
peptide is used to validate the identity of the target to avoid false identifications [149]. 
Recently, a new MS/MS approach that bypasses the aforementioned problems has 
been developed. The basic principle of this approach is the fragmentation of all 
peptide precursors within a pre-defined m/z mass range [138]. Since in this case, the 
instrument does not depend on the input data, i.e. the selection of most intense peaks 
in MS spectra, this approach was termed data-independent acquisition (DIA) [167]. 
DIA data analysis is complicated because the MS/MS spectra contain information not 
from one (like in shotgun) but from multiple precursors. Several strategies were 
developed to optimize the DIA data analysis [172, 173]. Since DIA spectra contain 
information about all peptides present in the sample, the data can potentially be re-
analyzed to obtain new information. The retrospective aspect of this kind of analysis is 
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an important factor, especially in research fields with a limited amount of available 
information, e.g. ADP-ribosylation. With new targets identified every year, the 
possibility to re-analyze the data to obtain new insights into the molecular pathways of 
different conditions is extremely powerful. Thus, it would be important to test the 
applicability of DIA to a detection of ADP-ribosylated peptides.  
4.5. Oxidative stress-induced ADP-ribosylome 
Induction of PARylation during oxidative stress is well known [174]. Using the 
macrodomain Af1521 for the enrichment of ADP-ribosylated peptides, we were able 
to identify modified proteins and their acceptor sites in various cell lines. Independent 
of the cell line tested, a similar oxidative stress-induced ADP-ribosylome was present. 
The identified H2O2–induced ADP-ribosylome was mainly dependent on ARTD1. GO 
analysis revealed that identified ADP-ribosylated proteins are mainly nuclear proteins 
with DNA and RNA binding capacity. Moreover, the ADP-ribosylome is enriched for 
proteins that function as a part of macromolecular complex, which correlates with the 
ability of PAR to serve as a scaffold to induce complex formations.  
The so far identified ADP-ribosylated proteins are among the most abundant 
proteins in the nucleus (e.g. ARTD1, HNRNPU, and NPC1). From this observation, 
the concern arises about the target specificity of ARTD1. If the only function of 
protein ADP-ribosylation was to negatively charge DNA-associated proteins, causing, 
for instance, chromatin relaxation, then ARTD1 could randomly modify any proteins 
in its proximity. However, our published ADPr-ChAP analysis identified the 
accumulation of ADP-ribosylation in heterochromatic regions upon oxidative stress 
[79]. The fact that all tested cells had a core ADP-ribosylome also indicates that 
ARTD1 specifically modifies proteins to regulate certain pathways upon H2O2 
treatment. Moreover, the bias toward abundant proteins could be explained by the 
shortcomings of the shotgun MS/MS method. Due to the data-dependency of 
acquisition and the use of dynamic exclusion in the shotgun methods, low abundant 
proteins are rarely selected for fragmentation and thus are rarely identified in the 
samples. Nevertheless, to elucidate this “specificity“ aspect of oxidative stress-induced 
ADP-ribosylation, the functional consequence of ADP-ribosylation should be studied 
for every modified protein.  
Although the number of identified ADP-ribosylated proteins in oxidative stress 
increases every year, it is still too early to conclude that the complete ADP-ribosylome 
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has been identified. First of all, the known biases of developed enrichment methods 
obstruct the complete ADP-ribosylome identification. Moreover, some known or 
expected ADP-ribosylation targets were not yet identified in cellular lysates. Despite 
the well-accepted theory that ARTD2 can functionally compensate for a lack of 
ARTD1 [71], only auto-modified ARTD1, but not ARTD2, was identified in the 
Af1521 pull-down. Interestingly, ARTD2 was detected when using the m-
aminophenylboronic bead enrichment method and lysates from MEFs (Figure 10). 
Moreover, when the protein was modified in vitro, we detected several ARTD2 ADP-
ribosylated auto-modification sites using m-aminophenylboronic bead. In contrast, 
similar experiments with Af1521 led to no assignment of ARTD2 modifications (data 
not shown). This discrepancy between enrichment methods indicates that the applied 
method protocol is biased towards some ADP-ribosylated targets. The PARG 
treatment could potentially be responsible for this loss of ARTD2 modification sites 
with Af1521. Although PARG is published to be unable to cleave the protein-bound 
ADP-ribose unit [175], our in vitro experiments indicate that this is not the case for all 
ADP-ribosylated proteins and that ARTD2 is completely demodified by PARG 
(personal observations by Jeannette Abplanalp). Treatment of the proteome with 
PARG is an important step to enable the detection of ADP-ribosylated peptides with 
MS/MS, since PARylated peptides have poor ionization capacity [125]. Thus, to avoid 
this bias but to still reduce complexity of the modification, an alternative to PARG 
treatment could be introduced. Ideally, this should be based on a chemical attack 
similar to the HA elution used in the m-aminophenylboronic beads enrichment [117] 
without a preference for certain acceptor sites. To our knowledge, such a treatment has 
yet to be developed.  
An additional possible optimization of the protocol, which might increase the 
number of identified ADP-ribosylated proteins upon oxidative stress and other 
conditions, would be to increase the binding affinity of the domain used for the 
enrichment. Af1521 possesses the highest known affinity (Kd ≈ 130 nM) among all 
known macrodomains [44]. However, this is not comparable to e.g. affinity of a 
specific antibody to its target. To identify ADP-ribosylated proteins, we currently 
process 15-20 mg of cell lysate [153]. The current enrichment method is unable to 
amplify enough modified peptides from less starting material. Although more sensitive 
methods such as PRM still perform well using only 5 mg of lysate [156], discovery 
proteomics methods need higher inputs to allow high confidence identifications [153, 
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160]. One of the possibilities to increase the affinity of the Af1521 domain used for 
enrichment is to perform a ribosomal display screen to detect mutants of the respective 
domain with increased binding affinity [176]. 
4.6. Identification of an ADP-ribosylation motif  
Defining an ADP-ribosylation motif would be a step toward understanding the role of 
the modification in cells and linking it to specific writers. Such a motif would enable 
the search of ADP-ribosylated proteins using bioinformatics tools applied to protein  
databases. The identification and validation of novel ADP-ribosylation targets might 
help to predict the functional involvement of ADP-ribosylation in a specific pathway. 
However, the identification of a motif for ADP-ribosylation appeared to be a 
challenging task. Despite the identification of over 2000 mapped ADP-ribosylation 
sites to date [177], only a few motives have been proposed so far. Several aspects 
contribute to the failure of finding a motif.  
First of all, the presence of four possible acceptor sites and thus potentially 
different motifs contributes to the complexity of the motif search problem. In total, 18 
motifs were reported for E acceptor sites so far [117, 124]. Interestingly, the 
xxxxxxEPxxxxx motif was identified by two studies utilizing the m-
aminophenylboronic beads enrichment [117, 124]. Gibson et al. also suggest several 
enzyme specific motifs [124]. However, the majority of the proposed motifs have 
several possible acceptor sites present in their sequence near the assigned main site 
(e.g. ExxxKxxK, one of the ARTD3 motifs reported by Gibson et al., where E 
assigned to be the acceptor site). Indeed, we also frequently observed peptides with 
multiple possible ADP-ribosylation sites, which makes it difficult to precisely localize 
the site. Thus, careful assignment of the ADP-ribose acceptor site with a high 
confidence is critical in such cases. In general, the precise site assignment is difficult 
for bulky modifications like ADP-ribosylation due to the complete fragmentation of 
ADP-ribose and the usually poor peptide fragmentation upon HCD [125]. 
Nevertheless, advances in MS instrumentations drastically improved our ability to 
unambiguously assign ADP-ribose acceptor sites [155]. We recently reported three 
potential motives for K-acceptor sites (xxxxxxKSxxxxx, xxxxKSxxxxK, 
xxxxSKxxxxx). The motifs for R and D sites are still elusive due to the low number of 
identified proteins with these ADP-ribose acceptor sites.  
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A second aspect making identification of motif difficult relates to a potential 
redundancy in ARTD activities. Oxidative stress induces the activity of ARTD1, 2, 
and 3 [61]. Proteomics studies reveal that the targets of these ARTDs overlap [124]. 
Although they modify the same protein, it is not clear if they modify the same acceptor 
sites. Moreover, several cytoplasmic proteins were identified in our oxidative stress-
induced ADP-ribosylome. These observations indicate that ARTDs from the 
cytoplasm modify targets identified in our dataset. These ARTDs might have their 
own recognition motif. The contribution of different ARTDs to the oxidative stress-
induced ADP-ribosylome might obstruct the identification of ARTD1, ARTD2, and 
ARTD3 specific motifs. A possible method to prevent this kind of “contamination” 
would be to inhibit the activity of cytoplasmic ARTDs. However, there is still a lack 
of specific ARTD inhibitors. Furthermore, the question of substrate specificity is 
difficult to address based on the available enrichment methods since we are currently 
unable to distinguish between MARylation or PARylation. 
The presence of several possible ADP-ribosylation sites close to each other 
identified in the same protein raises the question whether an ADP-ribosylation motif 
exists at all. In many cases, we observed that the validation of identified ADP-ribose 
acceptor site is difficult with standard in vitro methods (unpublished observations). 
The mutation of potential ADP-ribose acceptor sites in many cases only leads to a 
reduction but not a complete loss of ADP-ribosylation [21, 153]. This observation 
might indicate that ARTDs could “jump” to the next available acceptor site as 
described for ubiquitination [178]. ARTDs possibly might not recognize a specific 
sequence but rather a structural domain of a protein that is modified under certain 
conditions. To address this question, a systematic study aiming at understanding the 
substrate specificity of ARTDs is essential. Peptide screening methods utilizing 
peptide libraries might be applied for this purpose [179].  
4.7. Crosstalk and interplay of ADP-ribosylation and other protein 
posttranslational modifications 
K sites can not only be ADP-ribosylated, but can also be modified by methylation, 
acetylation, ubiquitination, SUMOylation  and many other PTMs [180]. The identified 
K motif revealed the presence of an S adjacent (C-terminal or N-terminal) to the ADP-
ribose acceptor site [155]. This potentially points at a crosstalk with serin 
phosphorylation. Indeed, ARTD1 activity is regulated by phosphorylation [78, 181]. 
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However, the interplay between phosphorylation and ADP-ribosylation has not been 
studied so far. We observed a decrease in the level of ADP-ribosylation under low 
oxidative stress conditions (4-16 µM of H2O2) compared to untreated cells. One of the 
possible explanations might be that the targeted peptides are modified by another 
PTM, possibly phosphorylation. This would not allow us to detect the peptide with a 
targeted MS/MS approach due to a change in the m/z ratio. Potentially, low doses of 
H2O2 induce other signaling pathways and enzyme cascades to cope with the induced 
stress. This problem could be addressed on several levels. Firstly, transcriptome 
profiles of cells under low doses of H2O2 might reveal an upregulation of certain 
pathways, which could be regulated by known PTMs. Secondly, the peptides could be 
analysed for the presence of modification motifs (e.g. phosphorylation motif) in their 
sequence. Lastly, a DIA experiment with a subsequent data mining approach based on 
an educational guess could be performed inder the same oxidative stress conditions. A 
specific method containing the combination of the best-fitted PTMs for the ADP-
ribosylated peptides (containing e.g. acetylation, methylation, and phosphorylation) 
should be generated. The analysis of this data might lead to the discovery of additional 
interfering modifications.   
The crosstalk between acetylation is another possible yet unstudied field. We 
demonstrated that FEN1 K354 is an acceptor site for ADP-ribosylation in oxidative 
stress [153]. The same site is an acceptor of acetylation by p300 and thus inhibits 
FEN1 DNA binding and nuclease activity [182]. The potential regulation of FEN1 
activity by ADP-ribosylation is an interesting question for further studies.  
The interplay of ADP-ribosylation with ubiquitination was already demonstrated 
for RNF146, which can recognize ADP-ribosylated proteins and is also activated by 
ADP-ribosylation [183, 184]. Another example is ARTD9, which is predicted to be 
inactive, and interacts with the ubiquitin ligase DTX3L [185]. Recently, ARTD9 was 
identified as a binder of H2B E2 ADP-ribosylation (unpublished results, Roxane 
Feurer), which might indicate its functional involvement in epigenetic regulation. 
Recently, an interesting mechanism was suggested for bacterial ARTCs, which 
facilitates the ubiquitination reaction by bypassing E1 and E2 enzymes [186]. Working 
in a complex with an E3 ligase, ARTC was able to catalyze the addition of ubiquitin 
onto proteins. If the same mechanism occurred in eukaryotic cells, ARTD9 might be 
an ideal candidate fulfilling this function.  
150 
 
4.8. Investigating MARylated proteins 
The majority of published studies identifying modified proteins use conditions under 
which PARylation is catalyzed by enzymes like ARTD1 and 2, e.g. oxidative stress. 
Taking into account that the number of MARylating ARTDs is higher than the 
PARylating ones, the ability to define the status of mono-ADP-ribosylation is a critical 
step to fully understand the function of the modification. Both published data and our 
data indicate several potential MARylated proteins, e.g. ER proteins (i.e. PDIA1 and 
PDIA3), which are modified under basal (untreated) conditions as well as after 
oxidative stress [156]. Their distinct localization indicates that they are not targets of 
nuclear ARTDs. However, due to the affinity of Af1521 toward both PARylated and 
MARylated proteins as well as considering the PARG digestion step in our workflow 
[153], it is impossible to distinguish between different modification statuses. Thus, 
several optimizations in the workflow could be considered to enable the discrimination 
between PAR and MAR. First, the binding properties of different existing ADP-ribose 
binding domains could be analyzed. Some of the ADP-ribose binding domains are 
able to discriminate between MARylated and PARylated proteins. E.g., the WWE 
domain only binds PARylated proteins [2]. Indeed, the WWE was successfully applied 
in an ADP-ribosylation-ChAP protocol [79]. Its applicability for the enrichment in an 
MS proteomics approach remains to be evaluated. Other macrodomains have been 
reported to specificaly bind MARylated proteins [187]. Moreover, MacroD1 and 
MacroD2 mutated to their enzymatic inactive state could be promising candidates as 
they show binding affinity toward MARylated E and D only [47]. Moreover, several 
MARylated ARTDs have macrodomains in their structure. The ARTD8 macrodomain 
e.g. is capable of binding MARylated ARTD10 [14]. The use of these domains for 
proteomics studies could thus fill a gap and allow discriminating between protein 
MARylation and PARylation.  
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